

US Patent & Trademark Office

Patent Public Search | Text View

United States Patent	12383194
Kind Code	B2
Date of Patent	August 12, 2025
Inventor(s)	Al-Ali; Ammar et al.

Depth of consciousness monitor

Abstract

The present disclosure relates to physiological monitoring to determine the depth of consciousness of a patient under sedation. The monitor includes an EEG sensor and a depth of consciousness monitor. The depth of consciousness monitor can utilize treatment data, such as patient data and/or drug profile information with an EEG signal to determine whether the patient is adequately sedated.

Inventors: Al-Ali; Ammar (San Juan Capistrano, CA), Weber; Walter M. (Laguna Hills, CA), Kashif; Faisal (Irvine, CA), Usman; Mohammad (Mission Viejo, CA), Chandrasekaran; Balaji (Irvine, CA)

Applicant: Masimo Corporation (Irvine, CA)

Family ID: 1000008750083

Assignee: Masimo Corporation (Irvine, CA)

Appl. No.: 16/752303

Filed: January 24, 2020

Prior Publication Data

Document Identifier	Publication Date
US 20200229729 A1	Jul. 23, 2020

Related U.S. Application Data

division parent-doc US 13911939 20130606 US 10542903 child-doc US 16752303
us-provisional-application US 61703747 20120920
us-provisional-application US 61656974 20120607

Publication Classification

Int. Cl.: **A61B5/00** (20060101); **A61B5/372** (20210101); **A61B5/389** (20210101); **A61M5/172** (20060101)

U.S. Cl.:

CPC **A61B5/4821** (20130101); **A61B5/372** (20210101); **A61B5/389** (20210101); **A61B5/4839** (20130101); **A61M5/1723** (20130101); A61M2205/35 (20130101); A61M2205/502 (20130101); A61M2230/04 (20130101)

Field of Classification Search

USPC: None

References Cited

U.S. PATENT DOCUMENTS

Patent No.	Issued Date	Patentee Name	U.S. Cl.	CPC
3702431	12/1971	Pinckaers	N/A	N/A
3710041	12/1972	Hayashi et al.	N/A	N/A
3719830	12/1972	Ananiades	N/A	N/A
4610259	12/1985	Cohen et al.	N/A	N/A
4960128	12/1989	Gordon et al.	N/A	N/A
4964408	12/1989	Hink et al.	N/A	N/A
5041187	12/1990	Hink et al.	N/A	N/A
5069213	12/1990	Polczynski	N/A	N/A
5163438	12/1991	Gordon et al.	N/A	N/A
5319355	12/1993	Russek	N/A	N/A
5337744	12/1993	Branigan	N/A	N/A
5341805	12/1993	Stavridi et al.	N/A	N/A
D353195	12/1993	Savage et al.	N/A	N/A
D353196	12/1993	Savage et al.	N/A	N/A
5377676	12/1994	Vari et al.	N/A	N/A
D359546	12/1994	Savage et al.	N/A	N/A
5431170	12/1994	Mathews	N/A	N/A
5436499	12/1994	Namavar et al.	N/A	N/A
D361840	12/1994	Savage et al.	N/A	N/A
D362063	12/1994	Savage et al.	N/A	N/A
5452717	12/1994	Branigan et al.	N/A	N/A
D363120	12/1994	Savage et al.	N/A	N/A
5456252	12/1994	Vari et al.	N/A	N/A
5479934	12/1995	Imran	N/A	N/A
5482036	12/1995	Diab et al.	N/A	N/A
5490505	12/1995	Diab et al.	N/A	N/A
5494043	12/1995	O'Sullivan et al.	N/A	N/A
5533511	12/1995	Kaspari et al.	N/A	N/A
5534851	12/1995	Russek	N/A	N/A
5561275	12/1995	Savage et al.	N/A	N/A

5562002	12/1995	Lalin	N/A	N/A
5590649	12/1996	Caro et al.	N/A	N/A
5602924	12/1996	Durand et al.	N/A	N/A
5632272	12/1996	Diab et al.	N/A	N/A
5638816	12/1996	Kiani- Azarbayjany et al.	N/A	N/A
5638818	12/1996	Diab et al.	N/A	N/A
5645440	12/1996	Tobler et al.	N/A	N/A
5671914	12/1996	Kalkhoran et al.	N/A	N/A
5685299	12/1996	Diab et al.	N/A	N/A
5699808	12/1996	John	600/483	A61B 5/4821
5726440	12/1997	Kalkhoran et al.	N/A	N/A
D393830	12/1997	Tobler et al.	N/A	N/A
5743262	12/1997	Lepper, Jr. et al.	N/A	N/A
5747806	12/1997	Khalil et al.	N/A	N/A
5750994	12/1997	Schlager	N/A	N/A
5758644	12/1997	Diab et al.	N/A	N/A
5760910	12/1997	Lepper, Jr. et al.	N/A	N/A
5769785	12/1997	Diab et al.	N/A	N/A
5782757	12/1997	Diab et al.	N/A	N/A
5785659	12/1997	Caro et al.	N/A	N/A
5791347	12/1997	Flaherty et al.	N/A	N/A
5810734	12/1997	Caro et al.	N/A	N/A
5823950	12/1997	Diab et al.	N/A	N/A
5830131	12/1997	Caro et al.	N/A	N/A
5833618	12/1997	Caro et al.	N/A	N/A
5860919	12/1998	Kiani- Azarbayjany et al.	N/A	N/A
5890929	12/1998	Mills et al.	N/A	N/A
5904654	12/1998	Wohlmann et al.	N/A	N/A
5919134	12/1998	Diab	N/A	N/A
5934925	12/1998	Tobler et al.	N/A	N/A
5940182	12/1998	Lepper, Jr. et al.	N/A	N/A
5987343	12/1998	Kinast	N/A	N/A
5995855	12/1998	Kiani et al.	N/A	N/A
5997343	12/1998	Mills et al.	N/A	N/A
6002952	12/1998	Diab et al.	N/A	N/A
6010937	12/1999	Karam et al.	N/A	N/A
6011986	12/1999	Diab et al.	N/A	N/A
6016444	12/1999	John	N/A	N/A
6016449	12/1999	Fischell et al.	N/A	N/A
6027452	12/1999	Flaherty et al.	N/A	N/A
6036642	12/1999	Diab et al.	N/A	N/A
6040578	12/1999	Malin et al.	N/A	N/A
6045509	12/1999	Caro et al.	N/A	N/A
6066204	12/1999	Haven	N/A	N/A
6067462	12/1999	Diab et al.	N/A	N/A

6081735	12/1999	Diab et al.	N/A	N/A
6088607	12/1999	Diab et al.	N/A	N/A
6110522	12/1999	Lepper, Jr. et al.	N/A	N/A
6115673	12/1999	Malin et al.	N/A	N/A
6124597	12/1999	Shehada	N/A	N/A
6128521	12/1999	Marro et al.	N/A	N/A
6129675	12/1999	Jay	N/A	N/A
6144868	12/1999	Parker	N/A	N/A
6151516	12/1999	Kiani-Azarbayjany et al.	N/A	N/A
6152754	12/1999	Gerhardt et al.	N/A	N/A
6157850	12/1999	Diab et al.	N/A	N/A
6165005	12/1999	Mills et al.	N/A	N/A
6184521	12/2000	Coffin, IV et al.	N/A	N/A
6206830	12/2000	Diab et al.	N/A	N/A
6229856	12/2000	Diab et al.	N/A	N/A
6232609	12/2000	Snyder et al.	N/A	N/A
6236872	12/2000	Diab et al.	N/A	N/A
6241683	12/2000	Macklem et al.	N/A	N/A
6253097	12/2000	Aronow et al.	N/A	N/A
6255708	12/2000	Sudharsanan et al.	N/A	N/A
6256523	12/2000	Diab et al.	N/A	N/A
6263222	12/2000	Diab et al.	N/A	N/A
6278522	12/2000	Lepper, Jr. et al.	N/A	N/A
6280213	12/2000	Tobler et al.	N/A	N/A
6280381	12/2000	Malin et al.	N/A	N/A
6285896	12/2000	Tobler et al.	N/A	N/A
6301493	12/2000	Marro et al.	N/A	N/A
6308089	12/2000	von der Ruhr et al.	N/A	N/A
6317627	12/2000	Ennen et al.	N/A	N/A
6321100	12/2000	Parker	N/A	N/A
6325761	12/2000	Jay	N/A	N/A
6334065	12/2000	Al-Ali et al.	N/A	N/A
6343224	12/2001	Parker	N/A	N/A
6349228	12/2001	Kiani et al.	N/A	N/A
6360114	12/2001	Diab et al.	N/A	N/A
6366805	12/2001	Lutz	N/A	N/A
6368283	12/2001	Xu et al.	N/A	N/A
6371921	12/2001	Caro et al.	N/A	N/A
6377829	12/2001	Al-Ali	N/A	N/A
6388240	12/2001	Schulz et al.	N/A	N/A
6397091	12/2001	Diab et al.	N/A	N/A
6411373	12/2001	Garside et al.	N/A	N/A
6415167	12/2001	Blank et al.	N/A	N/A
6430437	12/2001	Marro	N/A	N/A
6430525	12/2001	Weber et al.	N/A	N/A
6463311	12/2001	Diab	N/A	N/A

6470199	12/2001	Kopotic et al.	N/A	N/A
6487429	12/2001	Hockersmith et al.	N/A	N/A
6501975	12/2001	Diab et al.	N/A	N/A
6505059	12/2002	Kollias et al.	N/A	N/A
6515273	12/2002	Al-Ali	N/A	N/A
6519487	12/2002	Parker	N/A	N/A
6525386	12/2002	Mills et al.	N/A	N/A
6526300	12/2002	Kiani et al.	N/A	N/A
6534012	12/2002	Hazen et al.	N/A	N/A
6541756	12/2002	Schulz et al.	N/A	N/A
6542764	12/2002	Al-Ali et al.	N/A	N/A
6580086	12/2002	Schulz et al.	N/A	N/A
6584336	12/2002	Ali et al.	N/A	N/A
6587196	12/2002	Stippick et al.	N/A	N/A
6587199	12/2002	Luu	N/A	N/A
6595316	12/2002	Cybulski et al.	N/A	N/A
6597932	12/2002	Tian et al.	N/A	N/A
6597933	12/2002	Kiani et al.	N/A	N/A
6606511	12/2002	Ali et al.	N/A	N/A
6632181	12/2002	Flaherty et al.	N/A	N/A
6635559	12/2002	Greenwald et al.	N/A	N/A
6639668	12/2002	Trepagnier	N/A	N/A
6640116	12/2002	Diab	N/A	N/A
6640117	12/2002	Makarewicz et al.	N/A	N/A
6643530	12/2002	Diab et al.	N/A	N/A
6650917	12/2002	Diab et al.	N/A	N/A
6654624	12/2002	Diab et al.	N/A	N/A
6654626	12/2002	Devlin et al.	N/A	N/A
6658276	12/2002	Kiani et al.	N/A	N/A
6661161	12/2002	Lanzo et al.	N/A	N/A
6671531	12/2002	Al-Ali et al.	N/A	N/A
6678543	12/2003	Diab et al.	N/A	N/A
6684090	12/2003	Ali et al.	N/A	N/A
6684091	12/2003	Parker	N/A	N/A
6697164	12/2003	Babayoff et al.	N/A	N/A
6697656	12/2003	Al-Ali	N/A	N/A
6697657	12/2003	Shehada et al.	N/A	N/A
6697658	12/2003	Al-Ali	N/A	N/A
RE38476	12/2003	Diab et al.	N/A	N/A
6699194	12/2003	Diab et al.	N/A	N/A
6714804	12/2003	Al-Ali et al.	N/A	N/A
RE38492	12/2003	Diab et al.	N/A	N/A
6721582	12/2003	Trepagnier et al.	N/A	N/A
6721585	12/2003	Parker	N/A	N/A
6725075	12/2003	Al-Ali	N/A	N/A
6728560	12/2003	Kollias et al.	N/A	N/A
6735459	12/2003	Parker	N/A	N/A
6738652	12/2003	Mattu et al.	N/A	N/A

6745060	12/2003	Diab et al.	N/A	N/A
6760607	12/2003	Al-Ali	N/A	N/A
6770028	12/2003	Ali et al.	N/A	N/A
6771994	12/2003	Kiani et al.	N/A	N/A
6788965	12/2003	Ruchti et al.	N/A	N/A
6792300	12/2003	Diab et al.	N/A	N/A
6813511	12/2003	Diab et al.	N/A	N/A
6816241	12/2003	Grubisic	N/A	N/A
6816741	12/2003	Diab	N/A	N/A
6822564	12/2003	Al-Ali	N/A	N/A
6826419	12/2003	Diab et al.	N/A	N/A
6830711	12/2003	Mills et al.	N/A	N/A
6850787	12/2004	Weber et al.	N/A	N/A
6850788	12/2004	Al-Ali	N/A	N/A
6852083	12/2004	Caro et al.	N/A	N/A
6861639	12/2004	Al-Ali	N/A	N/A
6876931	12/2004	Lorenz et al.	N/A	N/A
6898452	12/2004	Al-Ali et al.	N/A	N/A
6920345	12/2004	Al-Ali et al.	N/A	N/A
6931268	12/2004	Kiani- Azarbayjany et al.	N/A	N/A
6934570	12/2004	Kiani et al.	N/A	N/A
6939305	12/2004	Flaherty et al.	N/A	N/A
6943348	12/2004	Coffin, IV	N/A	N/A
6944501	12/2004	Pless	N/A	N/A
6950687	12/2004	Al-Ali	N/A	N/A
6956649	12/2004	Acosta et al.	N/A	N/A
6961598	12/2004	Diab	N/A	N/A
6970792	12/2004	Diab	N/A	N/A
6979812	12/2004	Al-Ali	N/A	N/A
6985764	12/2005	Mason et al.	N/A	N/A
6990364	12/2005	Ruchti et al.	N/A	N/A
6993371	12/2005	Kiani et al.	N/A	N/A
6996427	12/2005	Ali et al.	N/A	N/A
6998247	12/2005	Monfre et al.	N/A	N/A
6999904	12/2005	Weber et al.	N/A	N/A
7003338	12/2005	Weber et al.	N/A	N/A
7003339	12/2005	Diab et al.	N/A	N/A
7015451	12/2005	Dalke et al.	N/A	N/A
7024233	12/2005	Ali et al.	N/A	N/A
7027849	12/2005	Al-Ali	N/A	N/A
7030749	12/2005	Al-Ali	N/A	N/A
7039449	12/2005	Al-Ali	N/A	N/A
7041060	12/2005	Flaherty et al.	N/A	N/A
7044918	12/2005	Diab	N/A	N/A
7047054	12/2005	Benni	N/A	N/A
7048687	12/2005	Reuss et al.	N/A	N/A
7067893	12/2005	Mills et al.	N/A	N/A
7072701	12/2005	Chen et al.	N/A	N/A

D526719	12/2005	Richie, Jr. et al.	N/A	N/A
7096052	12/2005	Mason et al.	N/A	N/A
7096054	12/2005	Abdul-Hafiz et al.	N/A	N/A
D529616	12/2005	Deros et al.	N/A	N/A
7132641	12/2005	Schulz et al.	N/A	N/A
7133710	12/2005	Acosta et al.	N/A	N/A
7142901	12/2005	Kiani et al.	N/A	N/A
7149561	12/2005	Diab	N/A	N/A
7186966	12/2006	Al-Ali	N/A	N/A
7190261	12/2006	Al-Ali	N/A	N/A
7215984	12/2006	Diab	N/A	N/A
7215986	12/2006	Diab	N/A	N/A
7221971	12/2006	Diab	N/A	N/A
7225006	12/2006	Al-Ali et al.	N/A	N/A
7225007	12/2006	Al-Ali	N/A	N/A
RE39672	12/2006	Shehada et al.	N/A	N/A
7239905	12/2006	Kiani-Azarbayjany et al.	N/A	N/A
7245953	12/2006	Parker	N/A	N/A
7254429	12/2006	Schurman et al.	N/A	N/A
7254431	12/2006	Al-Ali	N/A	N/A
7254433	12/2006	Diab et al.	N/A	N/A
7254434	12/2006	Schulz et al.	N/A	N/A
7272425	12/2006	Al-Ali	N/A	N/A
7274955	12/2006	Kiani et al.	N/A	N/A
D554263	12/2006	Al-Ali	N/A	N/A
7280550	12/2006	Rosenboom	N/A	N/A
7280858	12/2006	Al-Ali et al.	N/A	N/A
7289835	12/2006	Mansfield et al.	N/A	N/A
7292883	12/2006	De Felice et al.	N/A	N/A
7295866	12/2006	Al-Ali	N/A	N/A
7308894	12/2006	Hickle	N/A	N/A
7328053	12/2007	Diab et al.	N/A	N/A
7332784	12/2007	Mills et al.	N/A	N/A
7340287	12/2007	Mason et al.	N/A	N/A
7341559	12/2007	Schulz et al.	N/A	N/A
7341599	12/2007	Peyman	N/A	N/A
7343186	12/2007	Lamego et al.	N/A	N/A
D566282	12/2007	Al-Ali et al.	N/A	N/A
7355512	12/2007	Al-Ali	N/A	N/A
7356365	12/2007	Schurman	N/A	N/A
7371981	12/2007	Abdul-Hafiz	N/A	N/A
7373193	12/2007	Al-Ali et al.	N/A	N/A
7373194	12/2007	Weber et al.	N/A	N/A
7376453	12/2007	Diab et al.	N/A	N/A
7377794	12/2007	Al Ali et al.	N/A	N/A
7377899	12/2007	Weber et al.	N/A	N/A
7383070	12/2007	Diab et al.	N/A	N/A

7395158	12/2007	Monfre et al.	N/A	N/A
7415297	12/2007	Al-Ali et al.	N/A	N/A
7428432	12/2007	Ali et al.	N/A	N/A
7438683	12/2007	Al-Ali et al.	N/A	N/A
7440787	12/2007	Diab	N/A	N/A
7454240	12/2007	Diab et al.	N/A	N/A
7467002	12/2007	Weber et al.	N/A	N/A
7469157	12/2007	Diab et al.	N/A	N/A
7471969	12/2007	Diab et al.	N/A	N/A
7471971	12/2007	Diab et al.	N/A	N/A
7483729	12/2008	Al-Ali et al.	N/A	N/A
7483730	12/2008	Diab et al.	N/A	N/A
7489958	12/2008	Diab et al.	N/A	N/A
7496391	12/2008	Diab et al.	N/A	N/A
7496393	12/2008	Diab et al.	N/A	N/A
D587657	12/2008	Al-Ali et al.	N/A	N/A
7499741	12/2008	Diab et al.	N/A	N/A
7499835	12/2008	Weber et al.	N/A	N/A
7500950	12/2008	Al-Ali et al.	N/A	N/A
7509154	12/2008	Diab et al.	N/A	N/A
7509494	12/2008	Al-Ali	N/A	N/A
7510849	12/2008	Schurman et al.	N/A	N/A
7514725	12/2008	Wojtczuk et al.	N/A	N/A
7519406	12/2008	Blank et al.	N/A	N/A
7526328	12/2008	Diab et al.	N/A	N/A
D592507	12/2008	Wachman et al.	N/A	N/A
7530942	12/2008	Diab	N/A	N/A
7530949	12/2008	Al Ali et al.	N/A	N/A
7530955	12/2008	Diab et al.	N/A	N/A
7563110	12/2008	Al-Ali et al.	N/A	N/A
7593230	12/2008	Abul-Haj et al.	N/A	N/A
7596398	12/2008	Al-Ali et al.	N/A	N/A
7606608	12/2008	Blank et al.	N/A	N/A
7618375	12/2008	Flaherty	N/A	N/A
7620674	12/2008	Ruchti et al.	N/A	N/A
D606659	12/2008	Kiani et al.	N/A	N/A
7629039	12/2008	Eckerbom et al.	N/A	N/A
7640140	12/2008	Ruchti et al.	N/A	N/A
7647083	12/2009	Al-Ali et al.	N/A	N/A
D609193	12/2009	Al-Ali et al.	N/A	N/A
D614305	12/2009	Al-Ali et al.	N/A	N/A
7697966	12/2009	Monfire et al.	N/A	N/A
7698105	12/2009	Ruchti et al.	N/A	N/A
RE41317	12/2009	Parker	N/A	N/A
RE41333	12/2009	Blank et al.	N/A	N/A
7729733	12/2009	Al-Ali et al.	N/A	N/A
7734320	12/2009	Al-Ali	N/A	N/A
7761127	12/2009	Al-Ali et al.	N/A	N/A
7761128	12/2009	Al-Ali et al.	N/A	N/A
7761146	12/2009	Carlson et al.	N/A	N/A

7764982	12/2009	Dalke et al.	N/A	N/A
D621516	12/2009	Kiani et al.	N/A	N/A
7791155	12/2009	Diab	N/A	N/A
7801581	12/2009	Diab	N/A	N/A
7822452	12/2009	Schurman et al.	N/A	N/A
RE41912	12/2009	Parker	N/A	N/A
7844313	12/2009	Kiani et al.	N/A	N/A
7844314	12/2009	Al-Ali	N/A	N/A
7844315	12/2009	Al-Ali	N/A	N/A
7865222	12/2010	Weber et al.	N/A	N/A
7873497	12/2010	Weber et al.	N/A	N/A
7880606	12/2010	Al-Ali	N/A	N/A
7880626	12/2010	Al-Ali et al.	N/A	N/A
7891355	12/2010	Al-Ali et al.	N/A	N/A
7894868	12/2010	Al-Ali et al.	N/A	N/A
7899507	12/2010	Al-Ali et al.	N/A	N/A
7899518	12/2010	Trepagnier et al.	N/A	N/A
7904132	12/2010	Weber et al.	N/A	N/A
7909772	12/2010	Popov et al.	N/A	N/A
7910875	12/2010	Al-Ali	N/A	N/A
7919713	12/2010	Al-Ali et al.	N/A	N/A
7937128	12/2010	Al-Ali	N/A	N/A
7937129	12/2010	Mason et al.	N/A	N/A
7937130	12/2010	Diab et al.	N/A	N/A
7941199	12/2010	Kiani	N/A	N/A
7951086	12/2010	Flaherty et al.	N/A	N/A
7957780	12/2010	Lamego et al.	N/A	N/A
7962188	12/2010	Kiani et al.	N/A	N/A
7962190	12/2010	Diab et al.	N/A	N/A
7976472	12/2010	Kiani	N/A	N/A
7988637	12/2010	Diab	N/A	N/A
7990382	12/2010	Kiani	N/A	N/A
7991446	12/2010	Al-Ali et al.	N/A	N/A
8000761	12/2010	Al-Ali	N/A	N/A
8008088	12/2010	Bellott et al.	N/A	N/A
RE42753	12/2010	Kiani- Azarbayjany et al.	N/A	N/A
8019400	12/2010	Diab et al.	N/A	N/A
8028701	12/2010	Al-Ali et al.	N/A	N/A
8029765	12/2010	Bellott et al.	N/A	N/A
8036727	12/2010	Schurman et al.	N/A	N/A
8036728	12/2010	Diab et al.	N/A	N/A
8046040	12/2010	Ali et al.	N/A	N/A
8046041	12/2010	Diab et al.	N/A	N/A
8046042	12/2010	Diab et al.	N/A	N/A
8048040	12/2010	Kiani	N/A	N/A
8050728	12/2010	Al-Ali et al.	N/A	N/A
RE43169	12/2011	Parker	N/A	N/A
8118620	12/2011	Al-Ali et al.	N/A	N/A

8126528	12/2011	Diab et al.	N/A	N/A
8128572	12/2011	Diab et al.	N/A	N/A
8130105	12/2011	Al-Ali et al.	N/A	N/A
8145287	12/2011	Diab et al.	N/A	N/A
8150487	12/2011	Diab et al.	N/A	N/A
8175672	12/2011	Parker	N/A	N/A
8180420	12/2011	Diab et al.	N/A	N/A
8182443	12/2011	Kiani	N/A	N/A
8185180	12/2011	Diab et al.	N/A	N/A
8190223	12/2011	Al-Ali et al.	N/A	N/A
8190227	12/2011	Diab et al.	N/A	N/A
8203438	12/2011	Kiani et al.	N/A	N/A
8203704	12/2011	Merritt et al.	N/A	N/A
8204566	12/2011	Schurman et al.	N/A	N/A
8219172	12/2011	Schurman et al.	N/A	N/A
8224411	12/2011	Al-Ali et al.	N/A	N/A
8228181	12/2011	Al-Ali	N/A	N/A
8229532	12/2011	Davis	N/A	N/A
8229533	12/2011	Diab et al.	N/A	N/A
8233955	12/2011	Al-Ali et al.	N/A	N/A
8244325	12/2011	Al-Ali et al.	N/A	N/A
8255026	12/2011	Al-Ali	N/A	N/A
8255027	12/2011	Al-Ali et al.	N/A	N/A
8255028	12/2011	Al-Ali et al.	N/A	N/A
8260577	12/2011	Weber et al.	N/A	N/A
8265723	12/2011	McHale et al.	N/A	N/A
8274360	12/2011	Sampath et al.	N/A	N/A
8280473	12/2011	Al-Ali	N/A	N/A
8301217	12/2011	Al-Ali et al.	N/A	N/A
8306596	12/2011	Schurman et al.	N/A	N/A
8310336	12/2011	Muhsin et al.	N/A	N/A
8315683	12/2011	Al-Ali et al.	N/A	N/A
RE43860	12/2011	Parker	N/A	N/A
8337403	12/2011	Al-Ali et al.	N/A	N/A
8346330	12/2012	Lamego	N/A	N/A
8353842	12/2012	Al-Ali et al.	N/A	N/A
8355766	12/2012	MacNeish, III et al.	N/A	N/A
8359080	12/2012	Diab et al.	N/A	N/A
8364223	12/2012	Al-Ali et al.	N/A	N/A
8364226	12/2012	Diab et al.	N/A	N/A
8374665	12/2012	Lamego	N/A	N/A
8385995	12/2012	Al-ali et al.	N/A	N/A
8385996	12/2012	Smith et al.	N/A	N/A
8388353	12/2012	Kiani et al.	N/A	N/A
8399822	12/2012	Al-Ali	N/A	N/A
8401602	12/2012	Kiani	N/A	N/A
8405608	12/2012	Al-Ali et al.	N/A	N/A
8414499	12/2012	Al-Ali et al.	N/A	N/A
8418524	12/2012	Al-Ali	N/A	N/A

8423106	12/2012	Lamego et al.	N/A	N/A
8428967	12/2012	Olsen et al.	N/A	N/A
8430817	12/2012	Al-Ali et al.	N/A	N/A
8437825	12/2012	Dalvi et al.	N/A	N/A
8455290	12/2012	Siskavich	N/A	N/A
8457703	12/2012	Al-Ali	N/A	N/A
8457707	12/2012	Kiani	N/A	N/A
8463349	12/2012	Diab et al.	N/A	N/A
8466286	12/2012	Bellot et al.	N/A	N/A
8471713	12/2012	Poeze et al.	N/A	N/A
8473020	12/2012	Kiani et al.	N/A	N/A
8483787	12/2012	Al-Ali et al.	N/A	N/A
8489364	12/2012	Weber et al.	N/A	N/A
8498684	12/2012	Weber et al.	N/A	N/A
8504128	12/2012	Blank et al.	N/A	N/A
8509867	12/2012	Workman et al.	N/A	N/A
8515509	12/2012	Bruinsma et al.	N/A	N/A
8523781	12/2012	Al-Ali	N/A	N/A
8529301	12/2012	Al-Ali et al.	N/A	N/A
8532727	12/2012	Ali et al.	N/A	N/A
8532728	12/2012	Diab et al.	N/A	N/A
D692145	12/2012	Al-Ali et al.	N/A	N/A
8547209	12/2012	Kiani et al.	N/A	N/A
8548548	12/2012	Al-Ali	N/A	N/A
8548549	12/2012	Schurman et al.	N/A	N/A
8548550	12/2012	Al-Ali et al.	N/A	N/A
8560032	12/2012	Al-Ali et al.	N/A	N/A
8560034	12/2012	Diab et al.	N/A	N/A
8570167	12/2012	Al-Ali	N/A	N/A
8570503	12/2012	Vo et al.	N/A	N/A
8571617	12/2012	Reichgott et al.	N/A	N/A
8571618	12/2012	Lamego et al.	N/A	N/A
8571619	12/2012	Al-Ali et al.	N/A	N/A
8577431	12/2012	Lamego et al.	N/A	N/A
8581732	12/2012	Al-Ali et al.	N/A	N/A
8584345	12/2012	Al-Ali et al.	N/A	N/A
8588880	12/2012	Abdul-Hafiz et al.	N/A	N/A
8600467	12/2012	Al-Ali et al.	N/A	N/A
8606342	12/2012	Diab	N/A	N/A
8626255	12/2013	Al-Ali et al.	N/A	N/A
8630691	12/2013	Lamego et al.	N/A	N/A
8634889	12/2013	Al-Ali et al.	N/A	N/A
8641631	12/2013	Sierra et al.	N/A	N/A
8652060	12/2013	Al-Ali	N/A	N/A
8663107	12/2013	Kiani	N/A	N/A
8666468	12/2013	Al-Ali	N/A	N/A
8667967	12/2013	Al-Ali et al.	N/A	N/A
8670811	12/2013	O'Reilly	N/A	N/A
8670814	12/2013	Diab et al.	N/A	N/A

8676286	12/2013	Weber et al.	N/A	N/A
8682407	12/2013	Al-Ali	N/A	N/A
RE44823	12/2013	Parker	N/A	N/A
RE44875	12/2013	Kiani et al.	N/A	N/A
8688183	12/2013	Bruinsma et al.	N/A	N/A
8690799	12/2013	Telfort et al.	N/A	N/A
8700112	12/2013	Kiani	N/A	N/A
8702627	12/2013	Telfort et al.	N/A	N/A
8706179	12/2013	Parker	N/A	N/A
8712494	12/2013	MacNeish, III et al.	N/A	N/A
8715206	12/2013	Telfort et al.	N/A	N/A
8718735	12/2013	Lamego et al.	N/A	N/A
8718737	12/2013	Diab et al.	N/A	N/A
8718738	12/2013	Blank et al.	N/A	N/A
8720249	12/2013	Al-Ali	N/A	N/A
8721541	12/2013	Al-Ali et al.	N/A	N/A
8721542	12/2013	Al-Ali et al.	N/A	N/A
8723677	12/2013	Kiani	N/A	N/A
8740792	12/2013	Kiani et al.	N/A	N/A
8754776	12/2013	Poeze et al.	N/A	N/A
8755535	12/2013	Telfort et al.	N/A	N/A
8755856	12/2013	Diab et al.	N/A	N/A
8755872	12/2013	Marinow	N/A	N/A
8761850	12/2013	Lamego	N/A	N/A
8764671	12/2013	Kiani	N/A	N/A
8768423	12/2013	Shakespeare et al.	N/A	N/A
8771204	12/2013	Telfort et al.	N/A	N/A
8777634	12/2013	Kiani et al.	N/A	N/A
8781543	12/2013	Diab et al.	N/A	N/A
8781544	12/2013	Al-Ali et al.	N/A	N/A
8781549	12/2013	Al-Ali et al.	N/A	N/A
8788003	12/2013	Schurman et al.	N/A	N/A
8790268	12/2013	Al-Ali	N/A	N/A
8801613	12/2013	Al-Ali et al.	N/A	N/A
8821397	12/2013	Al-Ali et al.	N/A	N/A
8821415	12/2013	Al-Ali et al.	N/A	N/A
8830449	12/2013	Lamego et al.	N/A	N/A
8831700	12/2013	Schurman et al.	N/A	N/A
8840549	12/2013	Al-Ali et al.	N/A	N/A
8847740	12/2013	Kiani et al.	N/A	N/A
8849365	12/2013	Smith et al.	N/A	N/A
8852094	12/2013	Al-Ali et al.	N/A	N/A
8852994	12/2013	Wojtczuk et al.	N/A	N/A
8868147	12/2013	Stippick et al.	N/A	N/A
8868150	12/2013	Al-Ali et al.	N/A	N/A
8870792	12/2013	Al-Ali et al.	N/A	N/A
8886271	12/2013	Kiani et al.	N/A	N/A
8888539	12/2013	Al-Ali et al.	N/A	N/A

8888708	12/2013	Diab et al.	N/A	N/A
8892180	12/2013	Weber et al.	N/A	N/A
8897847	12/2013	Al-Ali	N/A	N/A
8909310	12/2013	Lamego et al.	N/A	N/A
8911377	12/2013	Al-Ali	N/A	N/A
8912909	12/2013	Al-Ali et al.	N/A	N/A
8920317	12/2013	Al-Ali et al.	N/A	N/A
8921699	12/2013	Al-Ali et al.	N/A	N/A
8922382	12/2013	Al-Ali et al.	N/A	N/A
8929964	12/2014	Al-Ali et al.	N/A	N/A
8942777	12/2014	Diab et al.	N/A	N/A
8948834	12/2014	Diab et al.	N/A	N/A
8948835	12/2014	Diab	N/A	N/A
8965471	12/2014	Lamego	N/A	N/A
8983564	12/2014	Al-Ali	N/A	N/A
8989831	12/2014	Al-Ali et al.	N/A	N/A
8996085	12/2014	Kiani et al.	N/A	N/A
8998809	12/2014	Kiani	N/A	N/A
9028429	12/2014	Telfort et al.	N/A	N/A
9037207	12/2014	Al-Ali et al.	N/A	N/A
9060721	12/2014	Reichgott et al.	N/A	N/A
9066666	12/2014	Kiani	N/A	N/A
9066680	12/2014	Al-Ali et al.	N/A	N/A
9072474	12/2014	Al-Ali et al.	N/A	N/A
9078560	12/2014	Schurman et al.	N/A	N/A
9084569	12/2014	Weber et al.	N/A	N/A
9095316	12/2014	Welch et al.	N/A	N/A
9106038	12/2014	Telfort et al.	N/A	N/A
9107625	12/2014	Telfort et al.	N/A	N/A
9107626	12/2014	Al-Ali et al.	N/A	N/A
9113831	12/2014	Al-Ali	N/A	N/A
9113832	12/2014	Al-Ali	N/A	N/A
9119595	12/2014	Lamego	N/A	N/A
9131881	12/2014	Diab et al.	N/A	N/A
9131882	12/2014	Al-Ali et al.	N/A	N/A
9131883	12/2014	Al-Ali	N/A	N/A
9131917	12/2014	Telfort et al.	N/A	N/A
9138180	12/2014	Coverston et al.	N/A	N/A
9138182	12/2014	Al-Ali et al.	N/A	N/A
9138192	12/2014	Weber et al.	N/A	N/A
9142117	12/2014	Muhsin et al.	N/A	N/A
9153112	12/2014	Kiani et al.	N/A	N/A
9153121	12/2014	Kiani et al.	N/A	N/A
9161696	12/2014	Al-Ali et al.	N/A	N/A
9161713	12/2014	Al-Ali et al.	N/A	N/A
9167995	12/2014	Lamego et al.	N/A	N/A
9176141	12/2014	Al-Ali et al.	N/A	N/A
9186102	12/2014	Bruinsma et al.	N/A	N/A
9192312	12/2014	Al-Ali	N/A	N/A
9192329	12/2014	Al-Ali	N/A	N/A

9192330	12/2014	Lin	N/A	N/A
9192351	12/2014	Telfort et al.	N/A	N/A
9195385	12/2014	Al-Ali et al.	N/A	N/A
9211072	12/2014	Kiani	N/A	N/A
9211095	12/2014	Al-Ali	N/A	N/A
9218454	12/2014	Kiani et al.	N/A	N/A
9226696	12/2015	Kiani	N/A	N/A
9241662	12/2015	Al-Ali et al.	N/A	N/A
9245668	12/2015	Vo et al.	N/A	N/A
9259185	12/2015	Abdul-Hafiz et al.	N/A	N/A
9267572	12/2015	Barker et al.	N/A	N/A
9277880	12/2015	Poeze et al.	N/A	N/A
9289167	12/2015	Diab et al.	N/A	N/A
9295421	12/2015	Kiani et al.	N/A	N/A
9307928	12/2015	Al-Ali et al.	N/A	N/A
9323894	12/2015	Kiani	N/A	N/A
D755392	12/2015	Hwang et al.	N/A	N/A
9326712	12/2015	Kiani	N/A	N/A
9333316	12/2015	Kiani	N/A	N/A
9339220	12/2015	Lamego et al.	N/A	N/A
9341565	12/2015	Lamego et al.	N/A	N/A
9351673	12/2015	Diab et al.	N/A	N/A
9351675	12/2015	Al-Ali et al.	N/A	N/A
9364181	12/2015	Kiani et al.	N/A	N/A
9368671	12/2015	Wojtczuk et al.	N/A	N/A
9370325	12/2015	Al-Ali et al.	N/A	N/A
9370326	12/2015	McHale et al.	N/A	N/A
9370335	12/2015	Al-ali et al.	N/A	N/A
9375185	12/2015	Ali et al.	N/A	N/A
9386953	12/2015	Al-Ali	N/A	N/A
9386961	12/2015	Al-Ali et al.	N/A	N/A
9392945	12/2015	Al-Ali et al.	N/A	N/A
9397448	12/2015	Al-Ali et al.	N/A	N/A
9408542	12/2015	Kinast et al.	N/A	N/A
9436645	12/2015	Al-Ali et al.	N/A	N/A
9445759	12/2015	Lamego et al.	N/A	N/A
9466919	12/2015	Kiani et al.	N/A	N/A
9474474	12/2015	Lamego et al.	N/A	N/A
9480422	12/2015	Al-Ali	N/A	N/A
9480435	12/2015	Olsen	N/A	N/A
9492110	12/2015	Al-Ali et al.	N/A	N/A
9510779	12/2015	Poeze et al.	N/A	N/A
9517024	12/2015	Kiani et al.	N/A	N/A
9532722	12/2016	Lamego et al.	N/A	N/A
9538949	12/2016	Al-Ali et al.	N/A	N/A
9538980	12/2016	Telfort et al.	N/A	N/A
9549696	12/2016	Lamego et al.	N/A	N/A
9554737	12/2016	Schurman et al.	N/A	N/A
9560996	12/2016	Kiani	N/A	N/A

9560998	12/2016	Al-Ali et al.	N/A	N/A
9566019	12/2016	Al-Ali et al.	N/A	N/A
9579039	12/2016	Jansen et al.	N/A	N/A
9591975	12/2016	Dalvi et al.	N/A	N/A
9622692	12/2016	Lamego et al.	N/A	N/A
9622693	12/2016	Diab	N/A	N/A
D788312	12/2016	Al-Ali et al.	N/A	N/A
9636055	12/2016	Al-Ali et al.	N/A	N/A
9636056	12/2016	Al-Ali	N/A	N/A
9649054	12/2016	Lamego et al.	N/A	N/A
9662052	12/2016	Al-Ali et al.	N/A	N/A
9668679	12/2016	Schurman et al.	N/A	N/A
9668680	12/2016	Bruinsma et al.	N/A	N/A
9668703	12/2016	Al-Ali	N/A	N/A
9675286	12/2016	Diab	N/A	N/A
9687160	12/2016	Kiani	N/A	N/A
9693719	12/2016	Al-Ali et al.	N/A	N/A
9693737	12/2016	Al-Ali	N/A	N/A
9697928	12/2016	Al-Ali et al.	N/A	N/A
9712318	12/2016	Foerester et al.	N/A	N/A
9717425	12/2016	Kiani et al.	N/A	N/A
9717458	12/2016	Lamego et al.	N/A	N/A
9724016	12/2016	Al-Ali et al.	N/A	N/A
9724024	12/2016	Al-Ali	N/A	N/A
9724025	12/2016	Kiani et al.	N/A	N/A
9730640	12/2016	Diab et al.	N/A	N/A
9743887	12/2016	Al-Ali et al.	N/A	N/A
9749232	12/2016	Sampath et al.	N/A	N/A
9750442	12/2016	Olsen	N/A	N/A
9750443	12/2016	Smith et al.	N/A	N/A
9750461	12/2016	Telfort	N/A	N/A
9775545	12/2016	Al-Ali et al.	N/A	N/A
9775546	12/2016	Diab et al.	N/A	N/A
9775570	12/2016	Al-Ali	N/A	N/A
9778079	12/2016	Al-Ali et al.	N/A	N/A
9782077	12/2016	Lamego et al.	N/A	N/A
9782110	12/2016	Kiani	N/A	N/A
9787568	12/2016	Lamego et al.	N/A	N/A
9788735	12/2016	Al-Ali	N/A	N/A
9788768	12/2016	Al-Ali et al.	N/A	N/A
9795300	12/2016	Al-Ali	N/A	N/A
9795310	12/2016	Al-Ali	N/A	N/A
9795358	12/2016	Telfort et al.	N/A	N/A
9795739	12/2016	Al-Ali et al.	N/A	N/A
9801556	12/2016	Kiani	N/A	N/A
9801588	12/2016	Weber et al.	N/A	N/A
9808188	12/2016	Perea et al.	N/A	N/A
9814418	12/2016	Weber et al.	N/A	N/A
9820691	12/2016	Kiani	N/A	N/A
9833152	12/2016	Kiani et al.	N/A	N/A

9833180	12/2016	Shakespeare et al.	N/A	N/A
9839379	12/2016	Al-Ali et al.	N/A	N/A
9839381	12/2016	Weber et al.	N/A	N/A
9847002	12/2016	Kiani et al.	N/A	N/A
9847749	12/2016	Kiani et al.	N/A	N/A
9848800	12/2016	Lee et al.	N/A	N/A
9848806	12/2016	Al-Ali et al.	N/A	N/A
9848807	12/2016	Lamego	N/A	N/A
9861298	12/2017	Eckerbom et al.	N/A	N/A
9861304	12/2017	Al-Ali et al.	N/A	N/A
9861305	12/2017	Weber et al.	N/A	N/A
9867578	12/2017	Al-Ali et al.	N/A	N/A
9872623	12/2017	Al-Ali	N/A	N/A
9876320	12/2017	Coverston et al.	N/A	N/A
9877650	12/2017	Muhsin et al.	N/A	N/A
9877686	12/2017	Al-Ali et al.	N/A	N/A
9891079	12/2017	Dalvi	N/A	N/A
9895107	12/2017	Al-Ali et al.	N/A	N/A
9913617	12/2017	Al-Ali et al.	N/A	N/A
9924893	12/2017	Schurman et al.	N/A	N/A
9924897	12/2017	Abdul-Hafiz	N/A	N/A
9936917	12/2017	Poeze et al.	N/A	N/A
9943269	12/2017	Muhsin et al.	N/A	N/A
9949676	12/2017	Al-Ali	N/A	N/A
9955937	12/2017	Telfort	N/A	N/A
9965946	12/2017	Al-Ali	N/A	N/A
9980667	12/2017	Kiani et al.	N/A	N/A
D820865	12/2017	Muhsin et al.	N/A	N/A
9986919	12/2017	Lamego et al.	N/A	N/A
9986952	12/2017	Dalvi et al.	N/A	N/A
9989560	12/2017	Poeze et al.	N/A	N/A
9993207	12/2017	Al-Ali et al.	N/A	N/A
10007758	12/2017	Al-Ali et al.	N/A	N/A
D822215	12/2017	Al-Ali et al.	N/A	N/A
D822216	12/2017	Barker et al.	N/A	N/A
10010276	12/2017	Al-Ali et al.	N/A	N/A
10032002	12/2017	Kiani et al.	N/A	N/A
10039482	12/2017	Al-Ali et al.	N/A	N/A
10052037	12/2017	Kinast et al.	N/A	N/A
10058275	12/2017	Al-Ali et al.	N/A	N/A
10064562	12/2017	Al-Ali	N/A	N/A
10086138	12/2017	Novak, Jr.	N/A	N/A
10092200	12/2017	Al-Ali et al.	N/A	N/A
10092249	12/2017	Kiani et al.	N/A	N/A
10098550	12/2017	Al-Ali et al.	N/A	N/A
10098591	12/2017	Al-Ali et al.	N/A	N/A
10098610	12/2017	Al-Ali et al.	N/A	N/A
10111591	12/2017	Dyell et al.	N/A	N/A
D833624	12/2017	DeJong et al.	N/A	N/A

10123726	12/2017	Al-Ali et al.	N/A	N/A
10123729	12/2017	Dyell et al.	N/A	N/A
10130289	12/2017	Al-Ali et al.	N/A	N/A
10130291	12/2017	Schurman et al.	N/A	N/A
D835282	12/2017	Barker et al.	N/A	N/A
D835283	12/2017	Barker et al.	N/A	N/A
D835284	12/2017	Barker et al.	N/A	N/A
D835285	12/2017	Barker et al.	N/A	N/A
10149616	12/2017	Al-Ali et al.	N/A	N/A
10154815	12/2017	Al-Ali et al.	N/A	N/A
10159412	12/2017	Lamego et al.	N/A	N/A
10188296	12/2018	Al-Ali et al.	N/A	N/A
10188331	12/2018	Al-Ali et al.	N/A	N/A
10188348	12/2018	Kiani et al.	N/A	N/A
RE47218	12/2018	Ali-Ali	N/A	N/A
RE47244	12/2018	Kiani et al.	N/A	N/A
RE47249	12/2018	Kiani et al.	N/A	N/A
10194847	12/2018	Al-Ali	N/A	N/A
10194848	12/2018	Kiani et al.	N/A	N/A
10201298	12/2018	Al-Ali et al.	N/A	N/A
10205272	12/2018	Kiani et al.	N/A	N/A
10205291	12/2018	Scruggs et al.	N/A	N/A
10213108	12/2018	Al-Ali	N/A	N/A
10219706	12/2018	Al-Ali	N/A	N/A
10219746	12/2018	McHale et al.	N/A	N/A
10226187	12/2018	Al-Ali et al.	N/A	N/A
10226576	12/2018	Kiani	N/A	N/A
10231657	12/2018	Al-Ali et al.	N/A	N/A
10231670	12/2018	Blank et al.	N/A	N/A
10231676	12/2018	Al-Ali et al.	N/A	N/A
RE47353	12/2018	Kiani et al.	N/A	N/A
10251585	12/2018	Al-Ali et al.	N/A	N/A
10251586	12/2018	Lamego	N/A	N/A
10255994	12/2018	Sampath et al.	N/A	N/A
10258265	12/2018	Poeze et al.	N/A	N/A
10258266	12/2018	Poeze et al.	N/A	N/A
10271748	12/2018	Al-Ali	N/A	N/A
10278626	12/2018	Schurman et al.	N/A	N/A
10278648	12/2018	Al-Ali et al.	N/A	N/A
10279247	12/2018	Kiani	N/A	N/A
10292628	12/2018	Poeze et al.	N/A	N/A
10292657	12/2018	Abdul-Hafiz et al.	N/A	N/A
10292664	12/2018	Al-Ali	N/A	N/A
10299708	12/2018	Poeze et al.	N/A	N/A
10299709	12/2018	Perea et al.	N/A	N/A
10299720	12/2018	Brown et al.	N/A	N/A
10305775	12/2018	Lamego et al.	N/A	N/A
10307111	12/2018	Muhsin et al.	N/A	N/A
10325681	12/2018	Sampath et al.	N/A	N/A

10327337	12/2018	Triman et al.	N/A	N/A
10327713	12/2018	Barker et al.	N/A	N/A
10332630	12/2018	Al-Ali	N/A	N/A
10383520	12/2018	Wojtczuk et al.	N/A	N/A
10383527	12/2018	Al-Ali	N/A	N/A
10388120	12/2018	Muhsin et al.	N/A	N/A
D864120	12/2018	Forrest et al.	N/A	N/A
10441181	12/2018	Telfort et al.	N/A	N/A
10441196	12/2018	Eckerbom et al.	N/A	N/A
10448844	12/2018	Al-Ali et al.	N/A	N/A
10448871	12/2018	Al-Ali et al.	N/A	N/A
10456038	12/2018	Lamego et al.	N/A	N/A
10463340	12/2018	Telfort et al.	N/A	N/A
10471159	12/2018	Lapotko et al.	N/A	N/A
10505311	12/2018	Al-Ali et al.	N/A	N/A
10524738	12/2019	Olsen	N/A	N/A
10532174	12/2019	Al-Ali	N/A	N/A
10537285	12/2019	Shreim et al.	N/A	N/A
10542903	12/2019	Al-Ali et al.	N/A	N/A
10555678	12/2019	Dalvi et al.	N/A	N/A
10568553	12/2019	O'Neil et al.	N/A	N/A
RE47882	12/2019	Al-Ali	N/A	N/A
10608817	12/2019	Haider et al.	N/A	N/A
D880477	12/2019	Forrest et al.	N/A	N/A
10617302	12/2019	Al-Ali et al.	N/A	N/A
10617335	12/2019	Al-Ali et al.	N/A	N/A
10637181	12/2019	Al-Ali et al.	N/A	N/A
D886849	12/2019	Muhsin et al.	N/A	N/A
D887548	12/2019	Abdul-Hafiz et al.	N/A	N/A
D887549	12/2019	Abdul-Hafiz et al.	N/A	N/A
10667764	12/2019	Ahmed et al.	N/A	N/A
D890708	12/2019	Forrest et al.	N/A	N/A
10721785	12/2019	Al-Ali	N/A	N/A
10736518	12/2019	Al-Ali et al.	N/A	N/A
10750984	12/2019	Pauley et al.	N/A	N/A
D897098	12/2019	Al-Ali	N/A	N/A
10779098	12/2019	Iswanto et al.	N/A	N/A
10827961	12/2019	Iyengar et al.	N/A	N/A
10828007	12/2019	Telfort et al.	N/A	N/A
10832818	12/2019	Muhsin et al.	N/A	N/A
10849554	12/2019	Shreim et al.	N/A	N/A
10856750	12/2019	Indorf et al.	N/A	N/A
D906970	12/2020	Forrest et al.	N/A	N/A
D908213	12/2020	Abdul-Hafiz et al.	N/A	N/A
10918281	12/2020	Al-Ali et al.	N/A	N/A
10932705	12/2020	Muhsin et al.	N/A	N/A
10932729	12/2020	Kiani et al.	N/A	N/A

10939878	12/2020	Kiani et al.	N/A	N/A
10956950	12/2020	Al-Ali et al.	N/A	N/A
D916135	12/2020	Indorf et al.	N/A	N/A
D917046	12/2020	Abdul-Hafiz et al.	N/A	N/A
D917550	12/2020	Indorf et al.	N/A	N/A
D917564	12/2020	Indorf et al.	N/A	N/A
D917704	12/2020	Al-Ali et al.	N/A	N/A
10987066	12/2020	Chandran et al.	N/A	N/A
10991135	12/2020	Al-Ali et al.	N/A	N/A
D919094	12/2020	Al-Ali et al.	N/A	N/A
D919100	12/2020	Al-Ali et al.	N/A	N/A
11006867	12/2020	Al-Ali	N/A	N/A
D921202	12/2020	Al-Ali et al.	N/A	N/A
11024064	12/2020	Muhsin et al.	N/A	N/A
11026604	12/2020	Chen et al.	N/A	N/A
D925597	12/2020	Chandran et al.	N/A	N/A
D927699	12/2020	Al-Ali et al.	N/A	N/A
11076777	12/2020	Lee et al.	N/A	N/A
11114188	12/2020	Poeze et al.	N/A	N/A
D933232	12/2020	Al-Ali et al.	N/A	N/A
D933233	12/2020	Al-Ali et al.	N/A	N/A
D933234	12/2020	Al-Ali et al.	N/A	N/A
11145408	12/2020	Sampath et al.	N/A	N/A
11147518	12/2020	Al-Ali et al.	N/A	N/A
11185262	12/2020	Al-Ali et al.	N/A	N/A
11191484	12/2020	Kiani et al.	N/A	N/A
D946596	12/2021	Ahmed	N/A	N/A
D946597	12/2021	Ahmed	N/A	N/A
D946598	12/2021	Ahmed	N/A	N/A
D946617	12/2021	Ahmed	N/A	N/A
11272839	12/2021	Al-Ali et al.	N/A	N/A
11289199	12/2021	Al-Ali	N/A	N/A
RE49034	12/2021	Al-Ali	N/A	N/A
11298021	12/2021	Muhsin et al.	N/A	N/A
D950580	12/2021	Ahmed	N/A	N/A
D950599	12/2021	Ahmed	N/A	N/A
D950738	12/2021	Al-Ali et al.	N/A	N/A
D957648	12/2021	Al-Ali	N/A	N/A
11382567	12/2021	O'Brien et al.	N/A	N/A
11389093	12/2021	Triman et al.	N/A	N/A
11406286	12/2021	Al-Ali et al.	N/A	N/A
11417426	12/2021	Muhsin et al.	N/A	N/A
11439329	12/2021	Lamego	N/A	N/A
11445948	12/2021	Scruggs et al.	N/A	N/A
D965789	12/2021	Al-Ali et al.	N/A	N/A
D967433	12/2021	Al-Ali et al.	N/A	N/A
11464410	12/2021	Muhsin	N/A	N/A
11504058	12/2021	Sharma et al.	N/A	N/A
11504066	12/2021	Dalvi et al.	N/A	N/A

D971933	12/2021	Ahmed	N/A	N/A
D973072	12/2021	Ahmed	N/A	N/A
D973685	12/2021	Ahmed	N/A	N/A
D973686	12/2021	Ahmed	N/A	N/A
D974193	12/2022	Forrest et al.	N/A	N/A
D979516	12/2022	Al-Ali et al.	N/A	N/A
D980091	12/2022	Forrest et al.	N/A	N/A
11596363	12/2022	Lamego	N/A	N/A
11627919	12/2022	Kiani et al.	N/A	N/A
11637437	12/2022	Al-Ali et al.	N/A	N/A
D985498	12/2022	Al-Ali et al.	N/A	N/A
11653862	12/2022	Dalvi et al.	N/A	N/A
D989112	12/2022	Muhsin et al.	N/A	N/A
D989327	12/2022	Al-Ali et al.	N/A	N/A
11678829	12/2022	Al-Ali et al.	N/A	N/A
11679579	12/2022	Al-Ali	N/A	N/A
11684296	12/2022	Vo et al.	N/A	N/A
11692934	12/2022	Normand et al.	N/A	N/A
11701043	12/2022	Al-Ali et al.	N/A	N/A
D997365	12/2022	Hwang	N/A	N/A
11721105	12/2022	Ranasinghe et al.	N/A	N/A
11730379	12/2022	Ahmed et al.	N/A	N/A
D998625	12/2022	Indorf et al.	N/A	N/A
D998630	12/2022	Indorf et al.	N/A	N/A
D998631	12/2022	Indorf et al.	N/A	N/A
D999244	12/2022	Indorf et al.	N/A	N/A
D999245	12/2022	Indorf et al.	N/A	N/A
D999246	12/2022	Indorf et al.	N/A	N/A
11766198	12/2022	Pauley et al.	N/A	N/A
D1000975	12/2022	Al-Ali et al.	N/A	N/A
11803623	12/2022	Kiani et al.	N/A	N/A
11832940	12/2022	Diab et al.	N/A	N/A
D1013179	12/2023	Al-Ali et al.	N/A	N/A
11872156	12/2023	Telfort et al.	N/A	N/A
11879960	12/2023	Ranasinghe et al.	N/A	N/A
11883129	12/2023	Olsen	N/A	N/A
D1022729	12/2023	Forrest et al.	N/A	N/A
11951186	12/2023	Krishnamani et al.	N/A	N/A
11974833	12/2023	Forrest et al.	N/A	N/A
11986067	12/2023	Al-Ali et al.	N/A	N/A
11986289	12/2023	Dalvi et al.	N/A	N/A
11986305	12/2023	Al-Ali et al.	N/A	N/A
D1031729	12/2023	Forrest et al.	N/A	N/A
12004869	12/2023	Kiani et al.	N/A	N/A
12014328	12/2023	Wachman et al.	N/A	N/A
D1036293	12/2023	Al-Ali et al.	N/A	N/A
D1037462	12/2023	Al-Ali et al.	N/A	N/A
12029844	12/2023	Pauley et al.	N/A	N/A
12048534	12/2023	Vo et al.	N/A	N/A

12064217	12/2023	Ahmed et al.	N/A	N/A
12066426	12/2023	Lapotko et al.	N/A	N/A
D1041511	12/2023	Indorf et al.	N/A	N/A
D1042596	12/2023	DeJong et al.	N/A	N/A
D1042852	12/2023	Hwang	N/A	N/A
12076159	12/2023	Belur Nagaraj et al.	N/A	N/A
12082926	12/2023	Sharma et al.	N/A	N/A
D1044828	12/2023	Chandran et al.	N/A	N/A
D1048571	12/2023	Yu et al.	N/A	N/A
D1048908	12/2023	Al-Ali et al.	N/A	N/A
12106752	12/2023	Campbell et al.	N/A	N/A
12114974	12/2023	Al-Ali et al.	N/A	N/A
12126683	12/2023	Koo et al.	N/A	N/A
12127838	12/2023	Olsen et al.	N/A	N/A
12128213	12/2023	Kiani et al.	N/A	N/A
12131661	12/2023	Pauley et al.	N/A	N/A
D1050910	12/2023	Al-Ali et al.	N/A	N/A
12178572	12/2023	Pauley et al.	N/A	N/A
12178581	12/2023	Telfort et al.	N/A	N/A
12178852	12/2023	Kiani et al.	N/A	N/A
D1057159	12/2024	DeJong et al.	N/A	N/A
D1057160	12/2024	DeJong et al.	N/A	N/A
12198790	12/2024	Al-Ali	N/A	N/A
12200421	12/2024	Campbell et al.	N/A	N/A
12207901	12/2024	Lapotko et al.	N/A	N/A
D1060680	12/2024	Al-Ali et al.	N/A	N/A
D1063893	12/2024	DeJong et al.	N/A	N/A
12235941	12/2024	Kiani et al.	N/A	N/A
12236767	12/2024	Muhsin	N/A	N/A
D1066244	12/2024	Lim et al.	N/A	N/A
D1066672	12/2024	Al-Ali et al.	N/A	N/A
2001/0034477	12/2000	Mansfield et al.	N/A	N/A
2001/0039483	12/2000	Brand et al.	N/A	N/A
2002/0010401	12/2001	Bushmakina et al.	N/A	N/A
2002/0058864	12/2001	Mansfield et al.	N/A	N/A
2002/0059159	12/2001	Cook	706/62	A61B 5/4094
2002/0117176	12/2001	Mantzaridis	128/204.23	A61B 5/1106
2002/0133080	12/2001	Apruzzese et al.	N/A	N/A
2002/0173729	12/2001	Viertio-Oja	600/544	A61B 5/374
2003/0013975	12/2002	Kiani	N/A	N/A
2003/0018243	12/2002	Gerhardt et al.	N/A	N/A
2003/0055355	12/2002	Viertio-Oja	600/544	A61B 5/16
2003/0144582	12/2002	Cohen et al.	N/A	N/A
2003/0145854	12/2002	Hickle	128/204.18	G16H 40/63
2003/0156288	12/2002	Barnum et al.	N/A	N/A
2003/0212312	12/2002	Coffin, IV et al.	N/A	N/A

2004/0038169	12/2003	Mandelkern et al.	N/A	N/A
2004/0073415	12/2003	Farhat	703/2	G06N 3/02
2004/0106163	12/2003	Workman, Jr. et al.	N/A	N/A
2004/0193068	12/2003	Burton	600/544	A61B 5/4812
2005/0007091	12/2004	Makeig	324/76.13	A61B 5/374
2005/0010116	12/2004	Korhonen	600/481	A61B 5/4035
2005/0055276	12/2004	Kiani et al.	N/A	N/A
2005/0124863	12/2004	Cook	600/300	A61B 5/4094
2005/0124888	12/2004	Jjt Rein	600/443	A61B 8/0833
2005/0234317	12/2004	Kiani	N/A	N/A
2006/0062432	12/2005	Watanabe	382/104	G08G 1/163
2006/0073719	12/2005	Kiani	N/A	N/A
2006/0149160	12/2005	Kofol	600/544	A61B 5/369
2006/0161054	12/2005	Reuss et al.	N/A	N/A
2006/0189871	12/2005	Al-Ali et al.	N/A	N/A
2007/0010756	12/2006	Viertio-Oja	600/544	G16H 50/50
2007/0055114	12/2006	Viertio-Oja	600/300	A61B 5/389
2007/0073116	12/2006	Kiani et al.	N/A	N/A
2007/0116119	12/2006	Wang	375/240.12	H04N 19/51
2007/0150025	12/2006	Dilorenzo	607/45	A61B 5/4094
2007/0180140	12/2006	Welch et al.	N/A	N/A
2007/0208322	12/2006	Rantala et al.	N/A	N/A
2007/0244377	12/2006	Cozad et al.	N/A	N/A
2007/0282478	12/2006	Al-Ali et al.	N/A	N/A
2008/0064965	12/2007	Jay et al.	N/A	N/A
2008/0094228	12/2007	Welch et al.	N/A	N/A
2008/0103375	12/2007	Kiani	N/A	N/A
2008/0107307	12/2007	Altherr	382/107	H04N 5/23248
2008/0117968	12/2007	Wang	375/240.12	H04N 19/61
2008/0204566	12/2007	Yamazaki	348/208.99	G03B 5/00
2008/0221418	12/2007	Al-Ali et al.	N/A	N/A
2008/0234598	12/2007	Snyder	600/545	A61B 5/374
2009/0036759	12/2008	Ault et al.	N/A	N/A
2009/0093687	12/2008	Telfort	600/300	A61B 5/318
2009/0095926	12/2008	MacNeish, III	N/A	N/A
2009/0131762	12/2008	Pelzek et al.	N/A	N/A
2009/0149148	12/2008	Kurtz	455/307	G06K 9/00536
2009/0160642	12/2008	Kim	N/A	N/A
2009/0198145	12/2008	Chow	514/1.1	A61K 31/137
2009/0247984	12/2008	Lamego et al.	N/A	N/A

2009/0275813	12/2008	Davis	N/A	N/A
2009/0275844	12/2008	Al-Ali	N/A	N/A
2009/0322865	12/2008	Wang	348/68	A61B 5/14539
2010/0004518	12/2009	Vo et al.	N/A	N/A
2010/0030040	12/2009	Poeze et al.	N/A	N/A
2010/0099964	12/2009	O'Reilly et al.	N/A	N/A
2010/0220180	12/2009	Lee	348/74	A61B 5/073
2010/0234718	12/2009	Sampath et al.	N/A	N/A
2010/0270257	12/2009	Wachman et al.	N/A	N/A
2010/0324441	12/2009	Hargrove et al.	N/A	N/A
2011/0028806	12/2010	Merritt et al.	N/A	N/A
2011/0028809	12/2010	Goodman	N/A	N/A
2011/0040197	12/2010	Welch et al.	N/A	N/A
2011/0054272	12/2010	Derchak	N/A	N/A
2011/0082711	12/2010	Poeze et al.	N/A	N/A
2011/0087081	12/2010	Kiani et al.	N/A	N/A
2011/0116547	12/2010	Chen	375/240.16	G06T 3/40
2011/0118561	12/2010	Tari et al.	N/A	N/A
2011/0125060	12/2010	Telfort	600/586	A61B 7/003
2011/0137297	12/2010	Kiani et al.	N/A	N/A
2011/0172498	12/2010	Olsen et al.	N/A	N/A
2011/0184307	12/2010	Hulin	N/A	N/A
2011/0208015	12/2010	Welch et al.	N/A	N/A
2011/0230733	12/2010	Al-Ali	N/A	N/A
2011/0270047	12/2010	O'Brien	N/A	N/A
2012/0044347	12/2011	Sugio	348/135	H04N 5/23296
2012/0053433	12/2011	Chamoun et al.	N/A	N/A
2012/0083673	12/2011	Al-Ali et al.	N/A	N/A
2012/0123231	12/2011	O'Reilly	N/A	N/A
2012/0165629	12/2011	Merritt et al.	N/A	N/A
2012/0203079	12/2011	McLaughlin	600/301	A61B 5/4094
2012/0203087	12/2011	McKenna	600/322	A61B 5/4821
2012/0209082	12/2011	Al-Ali	N/A	N/A
2012/0209084	12/2011	Olsen et al.	N/A	N/A
2012/0226117	12/2011	Lamego et al.	N/A	N/A
2012/0277548	12/2011	Burton	600/301	A61B 5/02405
2012/0283524	12/2011	Kiani et al.	N/A	N/A
2013/0023775	12/2012	Lamego et al.	N/A	N/A
2013/0041591	12/2012	Lamego	N/A	N/A
2013/0060147	12/2012	Welch et al.	N/A	N/A
2013/0096405	12/2012	Garfio	N/A	N/A
2013/0096936	12/2012	Sampath et al.	N/A	N/A
2013/0150748	12/2012	Jensen	N/A	N/A
2013/0197339	12/2012	Bardakjian	600/383	A61B 5/291
2013/0243021	12/2012	Siskavich	N/A	N/A

2013/0253334	12/2012	Al-Ali et al.	N/A	N/A
2013/0276785	12/2012	Melker et al.	N/A	N/A
2013/0296672	12/2012	O'Neil et al.	N/A	N/A
2013/0296713	12/2012	Al-Ali et al.	N/A	N/A
2013/0324808	12/2012	Al-Ali et al.	N/A	N/A
2013/0331660	12/2012	Al-Ali et al.	N/A	N/A
2013/0345921	12/2012	Al-Ali et al.	N/A	N/A
2014/0012100	12/2013	Al-Ali et al.	N/A	N/A
2014/0051953	12/2013	Lamego et al.	N/A	N/A
2014/0120564	12/2013	Workman et al.	N/A	N/A
2014/0121482	12/2013	Merritt et al.	N/A	N/A
2014/0127137	12/2013	Bellott et al.	N/A	N/A
2014/0163344	12/2013	Al-Ali	N/A	N/A
2014/0166076	12/2013	Kiani et al.	N/A	N/A
2014/0171763	12/2013	Diab	N/A	N/A
2014/0180038	12/2013	Kiani	N/A	N/A
2014/0180154	12/2013	Sierra et al.	N/A	N/A
2014/0180160	12/2013	Brown et al.	N/A	N/A
2014/0187973	12/2013	Brown	600/483	G16H 50/20
2014/0213864	12/2013	Abdul-Hafiz et al.	N/A	N/A
2014/0275835	12/2013	Lamego et al.	N/A	N/A
2014/0275871	12/2013	Lamego et al.	N/A	N/A
2014/0275872	12/2013	Merritt et al.	N/A	N/A
2014/0288400	12/2013	Diab et al.	N/A	N/A
2014/0316217	12/2013	Purdon et al.	N/A	N/A
2014/0316218	12/2013	Purdon et al.	N/A	N/A
2014/0316228	12/2013	Blank et al.	N/A	N/A
2014/0323825	12/2013	Al-Ali et al.	N/A	N/A
2014/0323897	12/2013	Brown et al.	N/A	N/A
2014/0323898	12/2013	Purdon et al.	N/A	N/A
2014/0330092	12/2013	Al-Ali et al.	N/A	N/A
2014/0330098	12/2013	Merritt et al.	N/A	N/A
2014/0357966	12/2013	Al-Ali et al.	N/A	N/A
2015/0005600	12/2014	Blank et al.	N/A	N/A
2015/0011907	12/2014	Purdon et al.	N/A	N/A
2015/0032029	12/2014	Al-Ali et al.	N/A	N/A
2015/0038859	12/2014	Dalvi et al.	N/A	N/A
2015/0073241	12/2014	Lamego	N/A	N/A
2015/0080754	12/2014	Purdon et al.	N/A	N/A
2015/0087936	12/2014	Al-Ali et al.	N/A	N/A
2015/0094546	12/2014	Al-Ali	N/A	N/A
2015/0099950	12/2014	Al-Ali et al.	N/A	N/A
2015/0101844	12/2014	Al-Ali et al.	N/A	N/A
2015/0106121	12/2014	Muhsin et al.	N/A	N/A
2015/0112151	12/2014	Muhsin et al.	N/A	N/A
2015/0142082	12/2014	Simon et al.	N/A	N/A
2015/0165312	12/2014	Kiani	N/A	N/A
2015/0196249	12/2014	Brown et al.	N/A	N/A
2015/0216459	12/2014	Al-Ali et al.	N/A	N/A

2015/0238722	12/2014	Al-Ali	N/A	N/A
2015/0245773	12/2014	Lamego et al.	N/A	N/A
2015/0245794	12/2014	Al-Ali	N/A	N/A
2015/0257689	12/2014	Al-Ali et al.	N/A	N/A
2015/0272508	12/2014	Chiouchang et al.	N/A	N/A
2015/0272514	12/2014	Kiani et al.	N/A	N/A
2015/0306390	12/2014	Zalay	607/45	A61N 1/36064
2015/0351697	12/2014	Weber et al.	N/A	N/A
2015/0359429	12/2014	Al-Ali et al.	N/A	N/A
2015/0366507	12/2014	Blank	N/A	N/A
2016/0029932	12/2015	Al-Ali	N/A	N/A
2016/0058347	12/2015	Reichgott et al.	N/A	N/A
2016/0066824	12/2015	Al-Ali et al.	N/A	N/A
2016/0081552	12/2015	Wojtczuk et al.	N/A	N/A
2016/0095543	12/2015	Telfort et al.	N/A	N/A
2016/0095548	12/2015	Al-Ali et al.	N/A	N/A
2016/0103598	12/2015	Al-Ali et al.	N/A	N/A
2016/0166182	12/2015	Al-Ali et al.	N/A	N/A
2016/0166183	12/2015	Poeze et al.	N/A	N/A
2016/0196388	12/2015	Lamego	N/A	N/A
2016/0197436	12/2015	Barker et al.	N/A	N/A
2016/0213281	12/2015	Eckerbom et al.	N/A	N/A
2016/0228043	12/2015	O'Neil et al.	N/A	N/A
2016/0233632	12/2015	Scruggs et al.	N/A	N/A
2016/0234944	12/2015	Schmidt et al.	N/A	N/A
2016/0270735	12/2015	Diab et al.	N/A	N/A
2016/0283665	12/2015	Sampath et al.	N/A	N/A
2016/0287090	12/2015	Al-Ali et al.	N/A	N/A
2016/0287162	12/2015	Bardakjian	N/A	A61B 5/291
2016/0287786	12/2015	Kiani	N/A	N/A
2016/0296169	12/2015	McHale et al.	N/A	N/A
2016/0310052	12/2015	Al-Ali et al.	N/A	N/A
2016/0314260	12/2015	Kiani	N/A	N/A
2016/0324446	12/2015	Prerau	N/A	A61B 5/0533
2016/0324488	12/2015	Olsen	N/A	N/A
2016/0327984	12/2015	Al-Ali et al.	N/A	N/A
2016/0331332	12/2015	Al-Ali	N/A	N/A
2016/0367173	12/2015	Dalvi et al.	N/A	N/A
2017/0000394	12/2016	Al-Ali et al.	N/A	N/A
2017/0007134	12/2016	Al-Ali et al.	N/A	N/A
2017/0007198	12/2016	Al-Ali et al.	N/A	N/A
2017/0014083	12/2016	Diab et al.	N/A	N/A
2017/0014084	12/2016	Al-Ali et al.	N/A	N/A
2017/0024748	12/2016	Haider	N/A	N/A
2017/0042488	12/2016	Muhsin	N/A	N/A
2017/0055851	12/2016	Al-Ali	N/A	N/A
2017/0055882	12/2016	Al-Ali et al.	N/A	N/A

2017/0055887	12/2016	Al-Ali	N/A	N/A
2017/0055896	12/2016	Al-Ali et al.	N/A	N/A
2017/0079594	12/2016	Telfort et al.	N/A	N/A
2017/0086723	12/2016	Al-Ali et al.	N/A	N/A
2017/0143281	12/2016	Olsen	N/A	N/A
2017/0147774	12/2016	Kiani	N/A	N/A
2017/0156620	12/2016	Al-Ali et al.	N/A	N/A
2017/0173632	12/2016	Al-Ali	N/A	N/A
2017/0181693	12/2016	Kim et al.	N/A	N/A
2017/0187146	12/2016	Kiani et al.	N/A	N/A
2017/0188919	12/2016	Al-Ali et al.	N/A	N/A
2017/0196464	12/2016	Jansen et al.	N/A	N/A
2017/0196470	12/2016	Lamego et al.	N/A	N/A
2017/0224262	12/2016	Al-Ali	N/A	N/A
2017/0228516	12/2016	Sampath et al.	N/A	N/A
2017/0245790	12/2016	Al-Ali et al.	N/A	N/A
2017/0251974	12/2016	Shreim et al.	N/A	N/A
2017/0251975	12/2016	Shreim et al.	N/A	N/A
2017/0258403	12/2016	Abdul-Hafiz et al.	N/A	N/A
2017/0311851	12/2016	Schurman et al.	N/A	N/A
2017/0311891	12/2016	Kiani et al.	N/A	N/A
2017/0325728	12/2016	Al-Ali et al.	N/A	N/A
2017/0332976	12/2016	Al-Ali et al.	N/A	N/A
2017/0340293	12/2016	Al-Ali et al.	N/A	N/A
2017/0360310	12/2016	Kiani et al.	N/A	N/A
2017/0367632	12/2016	Al-Ali et al.	N/A	N/A
2018/0008146	12/2017	Al-Ali et al.	N/A	N/A
2018/0013562	12/2017	Haider et al.	N/A	N/A
2018/0014752	12/2017	Al-Ali et al.	N/A	N/A
2018/0028124	12/2017	Al-Ali et al.	N/A	N/A
2018/0055385	12/2017	Al-Ali	N/A	N/A
2018/0055390	12/2017	Kiani et al.	N/A	N/A
2018/0055430	12/2017	Diab et al.	N/A	N/A
2018/0064381	12/2017	Shakespeare et al.	N/A	N/A
2018/0069776	12/2017	Lamego et al.	N/A	N/A
2018/0070867	12/2017	Smith et al.	N/A	N/A
2018/0082767	12/2017	Al-Ali et al.	N/A	N/A
2018/0085068	12/2017	Telfort	N/A	N/A
2018/0087937	12/2017	Al-Ali et al.	N/A	N/A
2018/0103874	12/2017	Lee et al.	N/A	N/A
2018/0103905	12/2017	Kiani	N/A	N/A
2018/0110478	12/2017	Al-Ali	N/A	N/A
2018/0116575	12/2017	Perea et al.	N/A	N/A
2018/0125368	12/2017	Lamego et al.	N/A	N/A
2018/0125430	12/2017	Al-Ali et al.	N/A	N/A
2018/0125445	12/2017	Telfort et al.	N/A	N/A
2018/0130325	12/2017	Kiani et al.	N/A	N/A
2018/0132769	12/2017	Weber et al.	N/A	N/A

2018/0132770	12/2017	Lamego	N/A	N/A
2018/0146901	12/2017	Al-Ali et al.	N/A	N/A
2018/0146902	12/2017	Kiani et al.	N/A	N/A
2018/0153442	12/2017	Eckerbom et al.	N/A	N/A
2018/0153446	12/2017	Kiani	N/A	N/A
2018/0153447	12/2017	Al-Ali et al.	N/A	N/A
2018/0153448	12/2017	Weber et al.	N/A	N/A
2018/0161499	12/2017	Al-Ali et al.	N/A	N/A
2018/0168491	12/2017	Al-Ali et al.	N/A	N/A
2018/0174679	12/2017	Sampath et al.	N/A	N/A
2018/0174680	12/2017	Sampath et al.	N/A	N/A
2018/0182484	12/2017	Sampath et al.	N/A	N/A
2018/0184917	12/2017	Kiani	N/A	N/A
2018/0192924	12/2017	Al-Ali	N/A	N/A
2018/0192953	12/2017	Shreim et al.	N/A	N/A
2018/0192955	12/2017	Al-Ali et al.	N/A	N/A
2018/0199871	12/2017	Pauley et al.	N/A	N/A
2018/0206795	12/2017	Al-Ali	N/A	N/A
2018/0206815	12/2017	Telfort	N/A	N/A
2018/0213583	12/2017	Al-Ali	N/A	N/A
2018/0214031	12/2017	Kiani et al.	N/A	N/A
2018/0214090	12/2017	Al-Ali et al.	N/A	N/A
2018/0218792	12/2017	Muhsin et al.	N/A	N/A
2018/0225960	12/2017	Al-Ali et al.	N/A	N/A
2018/0238718	12/2017	Dalvi	N/A	N/A
2018/0242853	12/2017	Al-Ali	N/A	N/A
2018/0242921	12/2017	Muhsin et al.	N/A	N/A
2018/0242923	12/2017	Al-Ali et al.	N/A	N/A
2018/0242924	12/2017	Barker et al.	N/A	N/A
2018/0242926	12/2017	Muhsin et al.	N/A	N/A
2018/0247353	12/2017	Al-Ali et al.	N/A	N/A
2018/0247712	12/2017	Muhsin et al.	N/A	N/A
2018/0249933	12/2017	Schurman et al.	N/A	N/A
2018/0253947	12/2017	Muhsin et al.	N/A	N/A
2018/0256087	12/2017	Al-Ali et al.	N/A	N/A
2018/0256113	12/2017	Weber et al.	N/A	N/A
2018/0285094	12/2017	Housel et al.	N/A	N/A
2018/0289325	12/2017	Poeze et al.	N/A	N/A
2018/0289337	12/2017	Al-Ali et al.	N/A	N/A
2018/0296161	12/2017	Shreim et al.	N/A	N/A
2018/0300919	12/2017	Muhsin et al.	N/A	N/A
2018/0310822	12/2017	Indorf et al.	N/A	N/A
2018/0310823	12/2017	Al-Ali et al.	N/A	N/A
2018/0317826	12/2017	Muhsin	N/A	N/A
2018/0317841	12/2017	Novak, Jr.	N/A	N/A
2018/0333055	12/2017	Lamego et al.	N/A	N/A
2018/0333087	12/2017	Al-Ali	N/A	N/A
2019/0000317	12/2018	Muhsin et al.	N/A	N/A
2019/0000362	12/2018	Kiani et al.	N/A	N/A
2019/0015023	12/2018	Monfre	N/A	N/A

2019/0021638	12/2018	Al-Ali et al.	N/A	N/A
2019/0029574	12/2018	Schurman et al.	N/A	N/A
2019/0029578	12/2018	Al-Ali et al.	N/A	N/A
2019/0038143	12/2018	Al-Ali	N/A	N/A
2019/0058280	12/2018	Al-Ali et al.	N/A	N/A
2019/0058281	12/2018	Al-Ali et al.	N/A	N/A
2019/0069813	12/2018	Al-Ali	N/A	N/A
2019/0069814	12/2018	Al-Ali	N/A	N/A
2019/0076028	12/2018	Al-Ali et al.	N/A	N/A
2019/0082979	12/2018	Al-Ali et al.	N/A	N/A
2019/0090748	12/2018	Al-Ali	N/A	N/A
2019/0090760	12/2018	Kinast et al.	N/A	N/A
2019/0090764	12/2018	Al-Ali	N/A	N/A
2019/0104973	12/2018	Poeze et al.	N/A	N/A
2019/0110719	12/2018	Poeze et al.	N/A	N/A
2019/0117070	12/2018	Muhsin et al.	N/A	N/A
2019/0117139	12/2018	Al-Ali et al.	N/A	N/A
2019/0117140	12/2018	Al-Ali et al.	N/A	N/A
2019/0117141	12/2018	Al-Ali	N/A	N/A
2019/0117930	12/2018	Al-Ali	N/A	N/A
2019/0122763	12/2018	Sampath et al.	N/A	N/A
2019/0133525	12/2018	Al-Ali et al.	N/A	N/A
2019/0142283	12/2018	Lamego et al.	N/A	N/A
2019/0142344	12/2018	Telfort et al.	N/A	N/A
2019/0150800	12/2018	Poeze et al.	N/A	N/A
2019/0150856	12/2018	Kiani et al.	N/A	N/A
2019/0167161	12/2018	Al-Ali et al.	N/A	N/A
2019/0175019	12/2018	Al-Ali et al.	N/A	N/A
2019/0192076	12/2018	McHale et al.	N/A	N/A
2019/0200941	12/2018	Chandran et al.	N/A	N/A
2019/0239787	12/2018	Pauley et al.	N/A	N/A
2019/0320906	12/2018	Olsen	N/A	N/A
2019/0320988	12/2018	Ahmed et al.	N/A	N/A
2019/0374139	12/2018	Kiani et al.	N/A	N/A
2019/0374173	12/2018	Kiani et al.	N/A	N/A
2019/0374713	12/2018	Kiani et al.	N/A	N/A
2020/0021930	12/2019	Iswanto et al.	N/A	N/A
2020/0060869	12/2019	Telfort et al.	N/A	N/A
2020/0111552	12/2019	Ahmed	N/A	N/A
2020/0113435	12/2019	Muhsin	N/A	N/A
2020/0113488	12/2019	Al-Ali et al.	N/A	N/A
2020/0113496	12/2019	Scruggs et al.	N/A	N/A
2020/0113497	12/2019	Triman et al.	N/A	N/A
2020/0113520	12/2019	Abdul-Hafiz et al.	N/A	N/A
2020/0138288	12/2019	Al-Ali et al.	N/A	N/A
2020/0138368	12/2019	Kiani et al.	N/A	N/A
2020/0163597	12/2019	Dalvi et al.	N/A	N/A
2020/0196877	12/2019	Vo et al.	N/A	N/A
2020/0253474	12/2019	Muhsin et al.	N/A	N/A

2020/0253544	12/2019	Belur Nagaraj et al.	N/A	N/A
2020/0275841	12/2019	Telfort et al.	N/A	N/A
2020/0288983	12/2019	Telfort et al.	N/A	N/A
2020/0321793	12/2019	Al-Ali et al.	N/A	N/A
2020/0329983	12/2019	Al-Ali et al.	N/A	N/A
2020/0329984	12/2019	Al-Ali et al.	N/A	N/A
2020/0329993	12/2019	Al-Ali et al.	N/A	N/A
2020/0330037	12/2019	Al-Ali et al.	N/A	N/A
2021/0022628	12/2020	Telfort et al.	N/A	N/A
2021/0041953	12/2020	Poltorak	N/A	A61B 5/0077
2021/0104173	12/2020	Pauley et al.	N/A	N/A
2021/0113121	12/2020	Diab et al.	N/A	N/A
2021/0117525	12/2020	Kiani et al.	N/A	N/A
2021/0118581	12/2020	Kiani et al.	N/A	N/A
2021/0121582	12/2020	Krishnamani et al.	N/A	N/A
2021/0161465	12/2020	Barker et al.	N/A	N/A
2021/0236729	12/2020	Kiani et al.	N/A	N/A
2021/0256267	12/2020	Ranasinghe et al.	N/A	N/A
2021/0256835	12/2020	Ranasinghe et al.	N/A	N/A
2021/0275101	12/2020	Vo et al.	N/A	N/A
2021/0290060	12/2020	Ahmed	N/A	N/A
2021/0290072	12/2020	Forrest	N/A	N/A
2021/0290080	12/2020	Ahmed	N/A	N/A
2021/0290120	12/2020	Al-Ali	N/A	N/A
2021/0290177	12/2020	Novak, Jr.	N/A	N/A
2021/0290184	12/2020	Ahmed	N/A	N/A
2021/0296008	12/2020	Novak, Jr.	N/A	N/A
2021/0330228	12/2020	Olsen et al.	N/A	N/A
2021/0386382	12/2020	Olsen et al.	N/A	N/A
2021/0402110	12/2020	Pauley et al.	N/A	N/A
2022/0039707	12/2021	Sharma et al.	N/A	N/A
2022/0053892	12/2021	Al-Ali et al.	N/A	N/A
2022/0071562	12/2021	Kiani	N/A	N/A
2022/0096603	12/2021	Kiani et al.	N/A	N/A
2022/0151521	12/2021	Krishnamani et al.	N/A	N/A
2022/0218244	12/2021	Kiani et al.	N/A	N/A
2022/0287574	12/2021	Telfort et al.	N/A	N/A
2022/0296161	12/2021	Al-Ali et al.	N/A	N/A
2022/0361819	12/2021	Al-Ali et al.	N/A	N/A
2022/0379059	12/2021	Yu et al.	N/A	N/A
2022/0392610	12/2021	Kiani et al.	N/A	N/A
2023/0028745	12/2022	Al-Ali	N/A	N/A
2023/0038389	12/2022	Vo	N/A	N/A
2023/0045647	12/2022	Vo	N/A	N/A
2023/0058052	12/2022	Al-Ali	N/A	N/A
2023/0058342	12/2022	Kiani	N/A	N/A

2023/0069789	12/2022	Koo et al.	N/A	N/A
2023/0087671	12/2022	Telfort et al.	N/A	N/A
2023/0110152	12/2022	Forrest et al.	N/A	N/A
2023/0111198	12/2022	Yu et al.	N/A	N/A
2023/0115397	12/2022	Vo et al.	N/A	N/A
2023/0116371	12/2022	Mills et al.	N/A	N/A
2023/0135297	12/2022	Kiani et al.	N/A	N/A
2023/0138098	12/2022	Telfort et al.	N/A	N/A
2023/0145155	12/2022	Krishnamani et al.	N/A	N/A
2023/0147750	12/2022	Barker et al.	N/A	N/A
2023/0210417	12/2022	Al-Ali et al.	N/A	N/A
2023/0222805	12/2022	Muhsin et al.	N/A	N/A
2023/0222887	12/2022	Muhsin et al.	N/A	N/A
2023/0226331	12/2022	Kiani et al.	N/A	N/A
2023/0284916	12/2022	Telfort	N/A	N/A
2023/0284943	12/2022	Scruggs et al.	N/A	N/A
2023/0301562	12/2022	Scruggs et al.	N/A	N/A
2023/0346993	12/2022	Kiani et al.	N/A	N/A
2023/0368221	12/2022	Haider	N/A	N/A
2023/0371893	12/2022	Al-Ali et al.	N/A	N/A
2023/0389837	12/2022	Krishnamani et al.	N/A	N/A
2024/0016418	12/2023	Devadoss et al.	N/A	N/A
2024/0016419	12/2023	Devadoss et al.	N/A	N/A
2024/0047061	12/2023	Al-Ali et al.	N/A	N/A
2024/0049310	12/2023	Al-Ali et al.	N/A	N/A
2024/0049986	12/2023	Al-Ali et al.	N/A	N/A
2024/0081656	12/2023	DeJong et al.	N/A	N/A
2024/0122486	12/2023	Kiani	N/A	N/A
2024/0180456	12/2023	Al-Ali	N/A	N/A
2024/0188872	12/2023	Al-Ali et al.	N/A	N/A
2024/0245855	12/2023	Vo et al.	N/A	N/A
2024/0260894	12/2023	Olsen	N/A	N/A
2024/0267698	12/2023	Telfort et al.	N/A	N/A
2024/0277233	12/2023	Al-Ali	N/A	N/A
2024/0277280	12/2023	Al-Ali	N/A	N/A
2024/0298920	12/2023	Fernkbist et al.	N/A	N/A
2024/0306985	12/2023	Vo et al.	N/A	N/A
2024/0324953	12/2023	Telfort	N/A	N/A
2024/0380246	12/2023	Moran	N/A	N/A
2024/0380247	12/2023	Moran	N/A	N/A
2024/0404549	12/2023	Campbell et al.	N/A	N/A
2025/0000458	12/2024	Abdul-Hafiz et al.	N/A	N/A

FOREIGN PATENT DOCUMENTS

Patent No.	Application Date	Country	CPC
1 741 388	12/2006	EP	N/A

WO 02/032305	12/2001	WO	N/A
WO 2013/184965	12/2012	WO	N/A

OTHER PUBLICATIONS

US 2024/0016391 A1, 01/2024, Lapotko et al. (withdrawn) cited by applicant
Ionescu et al., C. M., Variable Time-Delay Estimation for Anesthesia Control During Intensive Care, IEEE Transactions on Biomedical Engineering, Feb. 1, 2011, pp. 363-369, vol. 58, No. 2, IEEE Service Center, Piscataway, NJ, USA. cited by applicant
International Search Report and Written Opinion received in PCT Application No. PCT/US2013/044598, dated Sep. 25, 2013. cited by applicant
Letter from Tara A. Ryan to Masimo Corporation re 510(k) No. K172890, U.S. Food & Drug Administration, dated Jan. 26, 2018 in 9 pages. cited by applicant
Letter from Todd D. Courtney to Masimo Corporation re 510(k) No. K203113, U.S. Food & Drug Administration, dated Feb. 25, 2022. cited by applicant

Primary Examiner: Nguyen; Anh Tuan T

Assistant Examiner: Woo; Jae

Attorney, Agent or Firm: Knobbe, Martens, Olson & Bear, LLP

Background/Summary

CROSS REFERENCE TO RELATED APPLICATIONS (1) This application is a divisional of U.S. application Ser. No. 13/911,939, filed Jun. 6, 2013, now U.S. Pat. No. 10,542,903, which claims the benefit of priority from U.S. Provisional No. 61/703,747, filed Sep. 20, 2012, and U.S. Provisional No. 61/656,974, filed Jun. 7, 2012, all of which are incorporated by reference in their entireties.

FIELD OF THE DISCLOSURE

(1) The present disclosure relates to the field of patient monitoring. In some embodiments, the disclosure relates to monitoring the depth of consciousness of a patient under anesthetic sedation.

BACKGROUND

(2) General anesthesia is often used to put patients to sleep and block pain and memory during medical or diagnostic procedures. While extremely useful, general anesthesia is not risk free. Caregivers therefore generally seek to maintain a depth of consciousness consistent with the needs of a particular medical procedure. Caregivers will monitor various physiological parameters of the patient to predict the patient's depth of consciousness. In response to monitored parameters, the caregiver may manually adjust the anesthetic dosage level to avoid over and under dosing. However, as a patient's depth of consciousness may frequently change, caregivers often employ a host of monitoring technologies to attempt to periodically, sporadically, or continually ascertain the wellness and consciousness of a patient. For example, caregivers may desire to monitor one or more of a patient's temperature, electroencephalogram or EEG, brain oxygen saturation, stimulus response, electromyography or EMG, respiration, body oxygen saturation or other blood analytes, pulse, hydration, blood pressure, perfusion, or other parameters or combinations of parameters. For many of the foregoing, monitoring technologies are individually readily available and widely used, such as, for example, pulse oximeters, vital signs monitors, and the like.

(3) In their depth of consciousness monitoring, caregivers may also use recording devices to acquire EEG signals. For example, caregivers place electrodes on the skin of the forehead to detect electrical activity produced by the firing of neurons within the brain. From patterns in the electrical

activity, caregivers attempt to determine, among other things, the state of consciousness of the brain. Caregivers may also use a pulse oximeter or cerebral oximetry to determine the percentage of oxygenation of the hemoglobin in the patient's blood. Caregivers may also use an EMG monitor to detect the muscular action and mechanical impulses generated by the musculature around the patient's forehead, among other bodily locations. Caregivers manually monitor such physiological parameters and then manually adjust anesthetic dosage.

(4) However, manual monitoring and dosage adjustment could lead to serious adverse results, including death, if improperly performed. In addition, typical depth of consciousness monitors do not account for variations in responses to sedation therapies that exist between patient demographics. Furthermore, typical depth of consciousness monitors do not account for differences in physiological responses that exists between particular sedation therapies and among different patient populations. Therefore, there remains a need in the art for a depth of consciousness monitor that is configured to automatically communicate with a caregiver and/or an anesthetic dosage device to provide accurate control over patient care by accounting for variations between populations and drug actions.

SUMMARY

(5) Based on at least the foregoing, the present disclosure seeks to overcome some or all of the drawbacks discussed above and provide additional advantages over prior technologies. The present disclosure describes embodiments of noninvasive methods, devices, and systems for monitoring depth of consciousness through brain electrical activity.

(6) In one embodiment, a depth of consciousness monitor is configured to determine the level of sedation of a medical patient. The depth of consciousness monitor includes: an EEG interface configured to receive an EEG signal from an EEG sensor; an EEG front end configured to pre-process the EEG signal; a processor, configured to determine a level of sedation of a medical patient based at least upon the pre-processed EEG signal, wherein the processor is further configured to determine delay information associated with the time the EEG signal is received and the time the level of sedation is determined; and a drug delivery device interface, configured to provide the level of sedation and the delay information to a drug delivery device.

(7) In some embodiments the EEG front end includes an EEG engine and an EMG engine configured to extract EEG information and EMG information from the EEG signal, respectively. In some embodiments, the processor is further configured to time stamp the EEG signal when received from the EEG sensor. In one embodiment, the depth of consciousness monitor also includes an additional sensor front end, such as an SpO2 sensor front end. In some embodiments, the depth of consciousness monitor also includes a data port configured to receive at least one of patient data and drug profile information. The processor may be configured to determine a level of sedation of a medical patient based at least upon the pre-processed EEG signal and the at least one of patient data and drug profile information. In some embodiments, the depth of consciousness monitor also includes the EEG sensor and/or the drug delivery system. In some embodiments, the drug delivery device interface includes a wireless communication device.

(8) In another embodiment, a depth of consciousness monitor is configured to determine the level of sedation of a medical patient. The depth of consciousness monitor includes: an EEG interface configured to receive an EEG signal from an EEG sensor; an EEG front end configured to pre-process the EEG signal; a processor, configured to determine a level of sedation of a medical patient based at least upon the pre-processed EEG signal, and a data port configured to transmit the patient sedation level. The processor can include: two or more computing engines, each configured to compute a possible sedation level according to a different process; and a decision logic module, configured to determine the patient's sedation level based at least upon the possible sedation level computations;

(9) In some embodiments, at least one of the computing engines is configured to implement a motion vector process, a phase coherence process, and/or utilize a brain model to compute one of

the possible sedation levels. The EEG front end may include an EEG engine and an EMG engine configured to extract EEG information and EMG information from the EEG signal, respectively. In some embodiments, the data port comprises a display and/or a wireless communication device.

(10) In yet another embodiment, a method of determining the level of sedation of a medical patient is provided. The method includes: receiving an EEG signal indicative of a medical patient's EEG; receiving treatment data associated with at least one of the medical patient and a drug to be delivered to the medical patient; and determining a level of sedation based at least upon the EEG signal and the treatment data.

(11) In some embodiments, the treatment data includes at least one of a patient age, age classification, sex, weight, body-mass index, a physiological parameters, a temperature, a blood oxygen concentration, an EMG signal, a drug type, a drug class, a mechanism of delivery, and an active ingredient. In some embodiments, determining a level of sedation comprises determining two or more possible levels of sedation with parallel computing engines and wherein said determining the level of sedation of the medical patient is based upon said possible levels of sedation. In some embodiments, determining the level of sedation comprises averaging two or more possible levels of sedation and/or selecting one of the possible levels of sedation as the level of sedation of the medical patient. In some embodiments, determining the possible levels of sedation is performed with motion vector analysis, phase coherence, and or by utilizing a brain model.

(12) For purposes of summarizing the disclosure, certain aspects, advantages and novel features of the disclosure have been described herein. Of course, it is to be understood that not necessarily all such aspects, advantages or features will be embodied in any particular embodiment of the disclosure.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

- (1) The following drawings and the associated descriptions are provided to illustrate embodiments of the present disclosure and do not limit the scope of the claims.
- (2) FIG. 1 illustrates an embodiment of a depth of consciousness monitoring system under closed-loop control.
- (3) FIG. 2 illustrates a block diagram of one embodiment of the depth of consciousness monitor of FIG. 1.
- (4) FIG. 3 illustrates one embodiment of the forehead sensor of FIG. 1.
- (5) FIG. 4 illustrates one embodiment of an EEG frequency spectrum of the patient before and during sedation using the depth of consciousness monitor of FIG. 2.
- (6) FIG. 5 illustrates one embodiment of the processor of the depth of consciousness monitor of FIG. 2.
- (7) FIG. 6 illustrates another embodiment of the processor of the depth of consciousness monitor of FIG. 2.
- (8) FIG. 7 illustrates yet another embodiment of the processor of the depth of consciousness monitor of FIG. 2.
- (9) FIG. 8 illustrates one embodiment of a routine to determine patient sedation information that can be performed by any of the processors of FIGS. 5-7.
- (10) FIG. 9 illustrates another embodiment of a routine to determine patient sedation information that can be performed by any of the processors of FIGS. 5-7.
- (11) FIG. 10 illustrates another embodiment of a depth of consciousness monitoring system.
- (12) FIG. 11 illustrates one embodiment of the depth of consciousness monitoring system of FIG. 10.

(13) FIG. 12 illustrates one embodiment of the depth of consciousness monitoring assembly of FIG. 10.

(14) FIG. 13 illustrates the depth of consciousness monitoring assembly of FIG. 12 attached to a sensor assembly.

(15) FIGS. 14-16 illustrate views of the display of a multi-parameter monitor displaying physiological signals received from the depth of consciousness monitor of FIG. 10.

DETAILED DESCRIPTION

(16) The present disclosure generally relates to patient monitoring devices. In order to provide a complete and accurate assessment of the state of a patient's various physiological systems, in an embodiment, a sensor may advantageously monitor one, multiple or combinations of EEG, EMG, cerebral oximetry, temperature, pulse oximetry, respiration, and other physiological parameters. In various embodiments, the sensor includes a disposable portion and reusable portion. For example, the disposable portion may advantageously include components near a measurement site surface (the patient's skin), including, for example, an EEG sensor, an EMG sensor, a temperature sensor, tape, adhesive elements, positioning elements, or the like. In addition, or alternatively, the reusable portion may advantageously include other components, circuitry or electronics, which, in some embodiments include time-of-use restrictions for quality control or the like. The reusable portion, can be used multiple times for a single patient, across different patients, or the like, often depending upon the effectiveness of sterilization procedures. The reusable components may include, for example, cerebral oximetry components, pulse oximetry components and other components to measure other various parameters.

(17) In an embodiment, the disposable portion of the sensor may include an inductance connection or other electrical connection to the reusable portion of the sensor. The physiological signals from all sensors can be transmitted through a common cable to a depth of consciousness monitor. In an embodiment, the depth of consciousness monitor may include an analog to digital converter, various electrical filters, and a microcontroller for processing and controlling the various sensor components.

(18) In an embodiment, a depth of consciousness monitor is configured to communicate with the forehead sensor and one or more host display and patient monitoring stations. In an embodiment, the patient monitoring station may be a pulse oximeter. In an embodiment, the pulse oximeter may perform integrated display, data monitoring and processing of patient parameters including a connection for power and data communication. In an embodiment, some or all communication may be through wired, wireless, or other electrical connections. In an embodiment, the depth of consciousness monitor may advantageously be housed in a portable housing. In such embodiments, the unit may advantageously be physically associated with a monitored patient, such as, for example, attached in an arm band, a patient bed pouch, a hood or hat, a pocket of a shirt, gown, or other clothing, or the like. In other embodiments, the unit may be entirely or partially housed in a cable connector. In an embodiment, the signal processing and condition unit and/or the depth of consciousness monitor could also monitor patient parameters through other sensors including, for example, ECG, SpO₂ from the earlobe, finger, forehead or other locations, blood pressure, respiration through acoustic or other monitoring technologies, or other clinically relevant physiological parameters.

(19) In an embodiment, the depth of consciousness monitor communicates with a sensor, such as a forehead sensor including one or more light sources configured to emit light at a patient's forehead. In an embodiment, the light source may include one or more emitters or emitter systems, such emitters or emitter systems may be embedded into a substrate. In various embodiments, the emitters could include light emitting diodes ("LEDs"), lasers, superluminescent LEDs or some other light emitting components. These components could be arranged in any pattern on the substrate and could be either a single light emitting source or several light emitting sources. In an embodiment, the emitting components could emit light that deflects off of reflective surfaces

associated with a cap of the substrate. The reflective cover could be any number of shapes or sizes and could be constructed to direct light to specific points or a point on the cap or substrate.

(20) In an embodiment, a multi-faceted splitting mirror could reflect light to an opening in the substrate that would allow the light to escape and be emitted to an emission detector in an embodiment also housed in the light source substrate. The emission detector may advantageously sample the light providing feedback usable to create an optical bench or at least optical bench properties of the light source, including, for example, determinations of intensity, wavelength, or the like. In an embodiment, the light source may include a polarized filter for adjusting the emitter light, in some embodiments before exiting an opening in the emitter or being detected by the emission detector.

(21) In an embodiment, a caregiver could analyze physiological information collected from the various sensors including a patient's temperature, EEG, brain oxygen saturation, stimulus response, electromyography or EMG, respiration using acoustic sensor applied to the through, body oxygen saturation, glucose concentration, or other blood analytes, pulse, hydration, blood pressure, perfusion, or other parameters or combinations of parameters to determine relevant information about the state of a patient's well-being. In another embodiment, a caregiver may advantageously analyze information collected from the various sensors to more completely assess the overall depth of a patient's sedation and obtain an assessment superior to an assessment derived from monitoring a single or a few of the parameters mentioned above.

(22) Reference will now be made to the Figures to discuss embodiments of the present disclosure.

(23) FIG. 1 illustrates one example of a depth of consciousness monitoring system **100**. In certain embodiments, the depth of consciousness monitoring system **100** measures one or more physiological parameters including cerebral electrical activity (e.g., via EEG), cerebral muscular activity (e.g., via EMG), temperature, cerebral oxygenation, including venous and arterial oxygenation, arterial oxygenation at various other points on the body, various other blood analytes, including total hemoglobin, glucose, lipids, stimulus response, electromyography or EMG, respiration, pulse, hydration, blood pressure, perfusion, or other parameters or combination of other physiologically relevant patient characteristics. The information from these physiological parameters can be evaluated using trend analysis, absolute and relative measures of certain parameters, combined or alone to evaluate the total wellness and current state of sedation of a patient.

(24) The depth of consciousness monitoring system **100** includes multiple or a single sensor **120** in communication with a depth of consciousness monitor **140** via a communications link **150**. In the illustrated embodiment, the depth of consciousness monitoring system **100** also includes a drug delivery device **160** that receives a control signal from the depth of consciousness monitor **140** via a control link **170**. The drug delivery device **160** provides one or more sedatives (e.g., narcotic, hypnotic, analgesic, opiate, etc.) to a patient **180** via a conduit **190**.

(25) The sensor **120** can include any variety of shapes and sizes, and could be applied to a variety of measurement sites on a patient's skin including any location on the forehead and temples or other location of the head. One example of a sensor **120** configured for placement on a patient's forehead is described below with respect to FIG. 3. The sensor **120** generally includes one or more electrodes and is configured to measure the electrical activity within the patient's head and generate an EEG signal, as discussed in further detail below.

(26) In some embodiments, the sensor's electrodes are designed to be placed at a measurement site covered with a patient's hair. A caregiver or patient may fasten the sensor **120** to the patient's head with a variety of mechanism including adhesive, straps, caps, combinations of the same, or other devices for fastening sensors to a patient's body or skin known in the art.

(27) In some embodiments, the communication link **150** and/or the control link **170** are wired electrical connections (e.g., an electrical cable, etc.). In other embodiments, the communication link **150** and/or the control link **170** utilize wireless communication to provide portability, and

greater flexibility in depth of consciousness monitor placement with respect to the drug delivery device **160**. Wireless communications also help accommodate an ambulatory patient, or other patient in transit. For example, in one embodiment, the depth of consciousness monitor **140** may be attached to an arm band or included in an arm band or other device that is wearable by the patient, including in a cap, a hood, a sling or a pocket of a garment. In such an embodiment, the sensor **120** communicates with the arm band depth of consciousness monitor **140** via a wired or a wireless connection.

(28) In an embodiment, the depth of consciousness monitor **140** communicates wirelessly with the drug delivery device **160** over a wireless control link **170**. This allows the depth of consciousness monitor **140** to be transported between various caregiving facilities, each with their own stationary drug delivery devices **160** without unhooking and reinserting hardwired electrical connections. Instead, the depth of consciousness monitor **140** could establish a wireless communication link with a stationary drug delivery device **160** as the depth of consciousness monitor **140** is brought into proximity with the drug delivery device **160**. In an embodiment, the devices could establish the connection automatically and patient data may be automatically sent from the depth of consciousness monitor **140** to the drug delivery device **160**. In other embodiments, caregiver interaction is required to establish a wireless control link **170** between the depth of consciousness monitor **140** and the drug delivery device **160**. Such configurations advantageously facilitate portability and seamless monitoring of a patient while the patient is transported, for example, from an ambulance to a hospital room or from room to room within a hospital.

(29) In an embodiment, the depth of consciousness monitor **140** also communicates with, or incorporates, a pulse oximeter (not shown). The pulse oximeter may be a multi-parameter monitor or other host device capable of monitoring a wide variety of vital signs and blood constituents and other parameters or combinations of parameters such as those monitors commercially available from Masimo Corporation of Irvine, CA, and disclosed herein with reference to U.S. Pat. Nos. 6,584,336, 6,661,161, 6,850,788, and 7,415,297, among others assigned to Masimo Corporation, and U.S. Patent Publication No. 2006/0211924, 2010/0030040, among others assigned to Masimo Corporation or Masimo Laboratories, Inc. of Irvine CA, all of which are incorporated by reference in their entireties.

(30) The communication link **150** and the control link **170** can include any of a variety of wired or wireless configurations. For example, in some embodiments the links **150**, **170** are implemented according to one or more of an IEEE 801.11x standard (e.g., a/b/g/n, etc.), a BLUETOOTH wireless standard, and a wireless medical information communications standard, etc.

(31) The drug delivery device **160** generally includes at least a drug therapy interface **192**, a drug flow device **194**, and a flow controller **196**. The drug therapy interface **192** receives a drug and provides a flow path to the drug flow device **194**. For example, the drug therapy interface **192** can include a port or receptacle to receive or interface with a drug capsule, intravenous bag, syringe, etc. The drug flow device **194** receives the drug therapy from the drug therapy interface **192** and allows the drug to flow to the patient **180** via the conduit **190**. In some embodiments, the drug flow device **194** includes one or more of a solenoid, a pump, a valve, a peristaltic pump, a variable speed pump, a compression sleeve (e.g., to squeeze an intravenous bag), etc. The action and activation of the drug flow device **194** is controlled by the flow controller **196**. The flow controller **196** includes a microcontroller, a memory, a signal input to receive a control signal from the depth of consciousness monitor **140** via the control link **170** and a signal output to provide control over the functionality of the drug flow device **194**. The signal input can include a wireless radio to facilitate wireless communication over a wireless control link **170**. The signal input allows closed-loop control over the operation of the drug delivery device **160**, as will be described in greater detail below.

(32) In some embodiments, the drug delivery device **160** is manually controlled by a clinician (e.g., an anesthesiologist) and/or includes a manual override to allow the clinician to take control over

drug delivery to the patient **180**. Therefore, in some embodiments, the depth of consciousness monitoring system **100** does not include an electronic control link **170** between the depth of consciousness monitor **140** and the drug delivery device. Instead, in such an open-loop configuration, the depth of consciousness monitor **140** displays an indication of the patient's depth of consciousness. The clinician is able to manually adjust drug therapy to the patient in response to the signals displayed by the depth of consciousness monitor **140**.

(33) In some embodiments, the depth of consciousness monitor **140** is configured to generate and/or provide a delay signal (which is a form of delay information) to the drug delivery device **160**. The delay signal may be used by the drug delivery device to control whether the depth of consciousness monitoring system **100** is operating under positive or negative feedback. In some embodiments, the drug delivery device **160** controls or delays the delivery of drugs provided to the patient **180** in response to the delay signal. For example, the drug delivery device **160** may delay drug delivery to make sure that the depth of consciousness monitoring system **100** is operating under negative feedback, and is therefore a stable control system.

(34) The delay signal can be determined by the depth of consciousness monitor **140** in any of a variety of manners. In one embodiment, the depth of consciousness monitor **140** time stamps the data received from the sensor **120** and provides the time stamp information or other related time information to the drug delivery device **160** as the delay signal. For example, in some embodiments, the delay signal includes the time stamp associated with the data received from the sensor **120** as well as a time stamp associated with the time the control signal data packet is sent to the drug delivery device **160**. In other embodiments, the delay signal includes the difference between the two time stamps. In some embodiments, the drug delivery device **160** is configured to calculate or otherwise determine the appropriate control delay based upon the delay signal. For example, the drug delivery device **160** may time stamp the time the control signal is received from the depth of consciousness monitor **140**. The drug delivery device **160** can determine a control delay based upon the difference between the time the control signal is received from the depth of consciousness monitor **140** and the time the depth of consciousness monitor received the signal from the sensor **120** that was used to generate the associated data packet received by the drug delivery device. The signal propagation delay through the depth of consciousness monitoring system **100** may be used to keep the system's feedback negative to avoid oscillation and to achieve stability.

(35) In an embodiment, a caregiver or the patient may attach the depth of consciousness monitor **140** directly to the patient's arm or other part or clothing of the patient through an armband with straps or some other means known in the art to connect a portable monitoring unit to a patient. In an embodiment, a depth of consciousness monitor **140** may be integrated into a hat or other headgear wearable by the patient or some other structure near the patient. In an embodiment, the depth of consciousness monitor **140** can rest on a table or other surface near the patient.

(36) In some embodiments, a depth of consciousness monitor **140** is integrated with the drug delivery device **160**. Alternatively, the depth of consciousness monitor **140** could be a module that is docked or otherwise attached to the drug delivery device **160**. The depth of consciousness monitor **140** can communicate with and/or be integrated with a variety of other device, such as a pulse oximeter, a respiration monitor, and EKG device, a blood pressure measurement device, a respirator, and/or a multi-parameter monitor.

(37) FIG. 2 illustrates a block diagram of one embodiment of the depth of consciousness monitor **140**, sensors **120**, and drug delivery device **160**. In an embodiment, the depth of consciousness monitor **140** includes a processor **220** which may be a micro-controller or other processor, to control and/or process signals received from the sensors **120**. For example, the processor **220** may coordinate, process or condition, or manipulate the signals received from the sensor **120** to generate electronic data, control signals, and/or delay signals that are subsequently displayed and/or communicated to the drug delivery device **160**. In addition, the processor **220** may receive

instructions or data control messages from the drug delivery device **160** or other patient monitoring device to provide the appropriate conditioning and controlling of the various front end components of the sensors **120**. Data transmitted between the depth of consciousness monitor **140**, the drug delivery device **160**, the sensors **120** and any other associated components, devices, or systems in communication with the depth of consciousness monitoring system **100** may be communicated by the devices using one or more interfaces, e.g., electrical wires, wireless communication, optical communication, RFID, LAN networks, or other electronic devices for communicating data known in the art. In one embodiment, a drug delivery device interface can include any one or more of electrical wires, wireless communication, optical communication, RFID, LAN networks, or other electronic devices for communicating data known in the art. In one embodiment, a multi-parameter physiological monitor interface can include any one or more of electrical wires, wireless communication, optical communication, RFID, LAN networks, or other electronic devices for communicating data known in the art.

(38) The depth of consciousness monitor **140** may also include various front end components to enable the depth of consciousness monitor **140** to process the various signals received by the various sensors **120** that may be communicating with the depth of consciousness monitor **140**. In an embodiment, front end components may translate and transmit instructions and control signals for driving the various sensors. In an embodiment, the front end components may translate, process, or transmit instructions and control signals to the emitting or light producing components of the sensor. The front end components may also receive and transmit data acquired by the detectors of the sensors to the microcontroller **220** or other processor **220**. The front end components can include one or more of an analog-to-digital converter, a preamplifier, an amplifier, a filter, a decimation filter, a demodulator, etc.

(39) These front end components could include front end components for a variety of sensors **120** including for sensors that detect blood oxygenation, EEG, EMG, ECG, temperature, acoustic respiration monitoring ("ARM") sensors, such as those available from Masimo Corporation of Irvine, CA, acoustic throat respiratory sensor, and brain oxygenation. In an embodiment, a caregiver could advantageously utilize a device with the ability to monitor the plurality of above mentioned parameters to more accurately determine a depth of a patient's sedation. However, in some embodiments, the depth of consciousness monitor **140** only includes EEG and EMG front end components. In an embodiment, a front end component that would be associated with a sensor **120** that detects brain oxygenation may have a sub component dedicated to driving emitters **230** associated with a light source of the brain oxygenation sensor and a sub-component associated with the detector **230** or detectors **230** of the brain oxygenation sensor **300** for receiving and transmitting the detected signals that pass through various body tissues. In other embodiments, the light drivers and detector front end are omitted.

(40) In an embodiment, one of the various sensors associated with the front end components of the brain oximetry unit could be, for example, a blood oxygenation sensor **310** which may be placed at various measurement sites on a patient's skin, including the earlobe, finger, forehead or other places known in the art suitable for detecting blood oxygenation. Many suitable pulse oximeter sensors **310** are known in the art such as those blood oxygenation sensors **310** commercially available from Masimo Corporation of Irvine, CA, including but not limited to those described in U.S. Pat. Nos. 5,638,818, 6,285,896, 6,377,829, 6,580,086, 6,985,764, and 7,341,559, which are expressly incorporated by reference in their entireties.

(41) In an embodiment, a temperature sensor **320** communicates with an associated front end component of the depth of consciousness monitor **140**. The temperature sensor **320** detects the temperature of the skin, the temperature inside the ear, the temperature under the tongue, or any other temperature measurement method known in the art. In an embodiment, the temperature sensor **320** could be any suitable thermistor, or any other temperature sensor **320** known in the art capable of detecting a surface temperature of a patient's skin. Additional temperature sensor may

advantageously provide feedback to the depth of consciousness monitor **140** regarding the performance or temperature of one, combinations of, or all of the emitters **230**.

(42) An EEG sensor **330** may also be associated with the front end components of the depth of consciousness monitor **140**. In an embodiment, the EEG sensor **330** may be any of a variety of EEG sensors **330** known in the art. An EEG sensor **330** could be applied to a patient at any of a multitude of locations and measurement sites on the skin of the head of a patient. In an embodiment, the EEG sensor **330** may include electrode leads that may be placed on a measurement site in contact with the skin of the patient. In an embodiment, the EEG **330** may monitor the electrical activity of a patient's brain through any number of electrodes, electrode leads, and channels or other systems known in the art. One such EEG sensor **330** is illustrated in FIG. 3 and described in greater detail below.

(43) In an embodiment, the EEG sensor **330** may monitor and collect data from a patient's brain using 4 channels and 6 electrodes. In another embodiment, the EEG **330** may use 3 channels and 5 electrodes. In another embodiment, any variety or combination of sensors maybe be used that are suitable for obtaining an EEG signal, such as those described in U.S. Pat. Nos. 60/164,444, 6,654,626, 6,128,521, which are incorporated by reference in their entireties.

(44) A brain oxygenation sensor **300** may also be associated with the front end components of the depth of consciousness monitor **140**. In an embodiment, the brain oxygenation sensor **300** includes a light source **230**, and a detector **260**. The light source **230** of the brain oxygenation sensor **300** includes emitter(s) that would emit light, sonic or other radiation into the forehead at one, two or other plurality of measurement sites located on the skin of the patient at a plurality of predetermined wavelengths. In an embodiment, the brain oxygenation sensor **300** would include a detector **260** with photodiodes or other radiation detection devices to detect the radiation emitting from the patient at a one or two or a plurality of measurement sites on the skin of the head of a patient. Many suitable brain oxygenation sensors **300** and cerebral oximeters are known in the art including those disclosed in U.S. Pat. Nos. 7,072,701, 7,047,054, which are expressly incorporated by reference in their entireties.

(45) In an embodiment, the light source **230** of the brain oxygenation sensor **300** may include an emission detector **260**. In an embodiment, the emission detector **260** detects the light emitted from the light source **230** before passing through or contacting the measurement site of the patient. In an embodiment, an output from the emission detector **230** would be communicated to the micro-controller **220** of the depth of consciousness monitor **140** in order to calculate an approximate output intensity of the light emitted by the emitter(s) **230**. The micro-controller **220** or other processor **220** could calculate the output intensity based on the output of the emission detector **260** by comparing the data to calibration data. In an embodiment, the calibration data could include measurement of intensity of light emitted from the emitter(s) **230** and corresponding measurements of output from the emission detector **260**. This data could then be correlated to real time output from the emission detector **260** while the oxygenation sensor **230** is in use to determine an actual or approximate intensity of light or radiation being emitted by the emitter(s) **230** utilizing a calibration curve or other suitable calculation or processing method. In an embodiment, the calibration data may be stored in an EPROM or other memory module in the depth of consciousness monitor **140** or other patient processing module or device associated with the patient monitoring system **100**.

(46) In an embodiment, the detector **260** detects light or other radiation emitted from the light source **230** after, in an embodiment, some of the light has entered the measurement site on the patient and has been attenuated by a patient's tissue. In an embodiment, the detector **260** could be any number of detectors known in the art for detecting light or other radiation including photodiodes or other types of light or radiation detectors. In one embodiment, the detector **260** may convert detected light or other radiation into a signal, for example, an electrical output signal, which may represent the intensity or other attributes of the radiation. In an embodiment, the signal from the detector **260** may be sent to a brain oxygenation detector **260** front end located in the

depth of consciousness monitor **140** for processing, conditioning or transmitting to a pulse oximeter (not shown) or other patient monitoring processor. In one embodiment, the signal may be converted into a digital format by an analog to digital converted located in the depth of consciousness monitor **140**. In an embodiment, the data from the detector **260** of the brain oxygenation sensor **300** may be processed to determine the cerebral oxygenation of a patient's brain tissue. In an embodiment, the processing of the data may include determining the changes of intensity between various wavelengths of emitted and detected light of the cerebral oxygenation sensor **300**.

(47) In an embodiment, a cerebral oximeter or multi-parameter monitor (not shown) acquires data from the depth of consciousness monitor **140** or sensor **120** derived from physiologically relevant parameters. In an embodiment, the pulse oximeter could provide visual quantitative or qualitative assessments of the patient's well-being based on one or more of the various parameters or physiological attributes measured.

(48) In an embodiment, a caregiver may utilize various physiological parameters to make a quantitative assessment of the patient's depth of sedation as indicated by an index based on for example, a patient's temperature, electroencephalogram or EEG, brain oxygen saturation, stimulus response, electromyography or EMG, respiration based on acoustic through sensors, body oxygen saturation or other blood analytes, pulse, hydration, blood pressure, perfusion, or other parameters or combinations of parameters. In another embodiment, various aspects of sedation could be assessed quantitatively or qualitatively based on a visual representation of the patient's sedation in the aspects including hypnosis, responsiveness, muscle relaxation or other clinically relevant facets of depth of anesthesia.

(49) In an embodiment, the functionality of the depth of consciousness monitor **140** could be optionally controlled by the drug delivery device **160**. In an embodiment, the data and qualitative and quantitative assessments of a patient's wellness being could be displayed on one or more of the depth of consciousness monitor **140**, the drug delivery device **160**, or any other device or system in communication with the depth of consciousness monitoring system **100** (e.g., a pulse oximeter, physiological patient monitor, nurse station, etc.). Also, audible alarms and other indicators could be displayed on either or both the depth of consciousness monitor **140** and drug delivery device in response to various threshold breaches based on the assessment of the patient's wellness and depth of consciousness as determined from the various monitored parameters.

(50) FIG. 3 illustrates one embodiments of a sensor **120** in the form of an EEG sensor **410**, which is configured for placement on a patient's forehead to generate an EEG signal. Disposable and reusable portions of the sensor **410** may be connected and overlaid on top of one another. The EEG sensor **410** includes six EEG electrodes **440** with two reference electrodes (along the central axis of the EEG sensor **410**) and four active channel electrodes (two on each side of the EEG sensor's central axis). In some embodiments, light source(s) and light detector(s) (not shown) may be incorporated into the EEG sensor **410**, as well. All or some of the above mentioned sensor components including the EEG electrodes **440**, leads from the electrodes **440**, and blood oxygen detecting light emitters and detectors (when provided) may communicate with one or more chips **420** that enables transmission of acquired signals and drive signals. In some embodiments a single chip **420** is provided. In other embodiments, each component communicates with its own individual chip through wires, or printed circuits, or other suitable electrical connections.

(51) The EEG electrodes **440** may be any suitable electrodes for detecting the electro-potentials on the surface of the skin of a patient's head. In one embodiment, EEG electrodes **440** include a metal or other suitable conductor and utilize leads contacting the surface of the skin. In another embodiment, the electrodes **440** are gelled electrodes that make contact through the skin via gel and have metal leads that come into contact with the gel. In still yet another embodiment, the EEG electrodes **440** may be glued to the forehead with any suitable patient dermal adhesive for connecting the EEG electrodes **440** and may have electrical conductivity. In an embodiment,

potentials from the EEG electrodes **440** are transmitted to the depth of consciousness monitor **140** for further conditioning, transmitting or processing.

(52) The sensor **410** may also include one or more temperature sensors (not shown). The temperature sensor may be any suitable sensor that can detect the temperature of the surface of the skin or other patient temperatures. In an embodiment, the temperature sensor may include a thermistor attached to a reusable portion of the sensor **410**.

(53) In an embodiment, the sensor **410** includes an interface **450** to couple the sensor **410** to the depth of consciousness monitor **140**. The interface **450** may be any suitable electrical or data connection or communication port or device including, for example, a pin connector and receiver. Various other communication or electrical connections known in the art may be utilized. In an embodiment, the interface **450** may include an inductance connection utilizing transformers to couple a data and electrical connection across an insulator. In another embodiment, the interface **450** provides a data or electronic coupling between a reusable portion and a disposable portion of the sensor **410**.

(54) In some embodiments, the sensor **410** includes a disposable portion (not shown) removably attached to a reusable portion (not shown). In an embodiment, the disposable portion attaches to a measurement site of a patient's head and provides a base to which the reusable portion may be docked, mated or connected. The disposable portion houses the components of the sensor **410** that may be less expensive than at least some of the components contained in the reusable portion, and therefore may be disposed after a single or multiple uses, either on the same patient or different patients. The disposable portion of the sensor **410** includes a tape substrate that provides a base or substrate to which at least some of the components of the disposable portion may adhere or be integrated. In an embodiment, the tape can be constructed from any suitable disposable material that will effectively hold the components included in the disposable portion to a patient's forehead or other measurement site. In an embodiment, the tape includes a suitable dermal adhesive on a patient side of the disposable portion for temporary adhesion of the sensor to a patient's skin.

(55) In an embodiment, the sensor **410** may include an adhesive tape **430** that supports the EEG electrodes **440**. In one embodiment, the EEG electrodes **440** may be fastened to the tape **430**. In an embodiment, the EEG electrodes **440** could be embedded in the tape **430** by any known adhesive in the sensor arts or any other suitable means for connecting the EEG electrodes **440** that would allow the EEG electrode **440** leads to be exposed on a patient side of tape **430** in an appropriate position to come in close proximity to a measurement site of a patient's skin. In an embodiment, EEG electrodes **440** may be gelled so that the gel contacts the electrodes and a measurement site of a patient's skin to provide an electrical path between the measurement site of the patient's skin and the EEG electrodes **440**. In an embodiment, the leads of the EEG electrodes **440** are connected to a chip **420** by wires or other suitable electrical connections, such as a printed circuit, flex circuit, etc.

(56) The sensor **410** may also include a temperature sensor (not shown). In an embodiment, the temperature sensor includes a thermistor with the thermistor leads exposed on a patient contacting side of the tape **430**, in order to facilitate the contacting of the leads of temperature sensor to a measurement site of a patient's skin. In an embodiment, the temperature sensor is connected to single chip through wires or other suitable electrical connections such as a flexible printed circuit. In an embodiment, the temperature sensor may be located anywhere on the tape **430**, the disposable portion or the reusable portion of the sensor **410** (if the sensor is provided with disposable and reusable portions). In an embodiment, the leads for the temperature sensor may be near the center of tape **430** or anywhere on the periphery of tape **430**.

(57) In some embodiments, the sensor **410** includes a pulse oximeter sensor (not shown). The pulse oximeter sensor can include an ear pulse oximeter sensor that emits and detects radiation to determine the oxygenation of the blood travelling through the arteries of the ear. Many suitable ear pulse oximeter sensors are known in the art such as those sensors commercially available from

Masimo Corporation and disclosed herein with reference to U.S. Pat. No. 7,341,599, which is expressly incorporated by reference in its entirety. In another embodiment, the pulse oximeter sensor may be a forehead pulse oximeter sensor or any other suitable pulse oximeter known in the art or disclosed herein. The pulse oximeter sensor may be connected to the sensor **410** through electrical wires, wirelessly or other suitable electrical or data connection. Data collected from the pulse oximeter sensor may be transmitted to the depth of consciousness monitor **140**, pulse oximeter, or both for conditioning and further processing.

(58) In some embodiments, signal processing and conditioning circuitry of depth of consciousness monitor configured to monitor the EEG signals of a patient and providing feedback on the depth of sedation or awareness of a patient undergoing anesthesia, may be partially or entirely incorporated into the sensor **410**. Sedation brain function monitors, including those similar to the SEDLINE sedation monitor commercially available from Masimo Corporation of Irvine, CA, as well as those described in U.S. Pat. Nos. 6,128,521, 6,301,493, 6,317,627, 6,430,437, all of which are expressly incorporated by reference in their entireties. For example, the sensor's connector or interface **450** may house the circuit board, with six channels for six detectors and a processor configured to determine depth of consciousness.

(59) Integration of all or the majority of the associated circuitry and processing components of several different patient monitoring sensors in a single sensor advantageously provides a caregiver a simple device that can be attached to the patient's forehead and/or other areas on the patient, to provide minimal discomfort to the patient and minimal amount of wires and connections to cause electrical interference with instruments in the hospital environment. Additionally, the caregiver will spend less time attaching various sensors to a patient where each would otherwise require its own associated monitoring station. Furthermore, integration of sensor processing components allows some of the processing components to have shared functionality and therefore saves considerably on manufacturing costs. For example, memory chips, processors, or other electrical components may be shared by the various sensors.

(60) EEG Signal Processing

(61) Referring again to FIG. 2, the depth of consciousness monitor's processor **220** is configured to receive at least an EEG signal from an EEG sensor **330** using an interface, such as an EEG interface **332** and process the EEG signal to determine the patient's depth of consciousness. In some embodiments, the processor **220** determines an index value between 0 and 100 to indicate depth of consciousness. The depth of consciousness monitor **140** may include a display, such as a monitor, LED, speaker, etc., to indicate the patient's depth of consciousness, e.g., the index value.

(62) In some embodiments, the processor **220** determines the frequency content of the EEG signal prior to administration of any sedatives as well as during sedation. FIG. 4 illustrates one embodiment of a graph **500** showing the patient's EEG's frequency content or frequency spectrum prior to sedation as curve **510** and during sedation as curve **530**. Shifting of the curve **510** amplitude at frequencies below 10 Hz, a drop in curve slope at frequencies above 10 Hz, and the formation or increase in the frequency curve **510** to form a local maximum (e.g., local maximum **540**) at 10 Hz each indicates that the patient has entered a sedated state.

(63) Indeed, in one embodiment, the processor **220** determines whether the patient is adequately sedated by monitoring for the presence of a local maximum **540** in the frequency curve **530** above a predetermined threshold value, at 10 Hz. However, the shape of the frequency curve **530** can vary based upon several factors, such as any one or more of the patient's age, age classification (e.g., pediatric, adult, geriatric, etc.), sex, weight, body-mass index, genetic factors, etc. The shape of the frequency curve **530** can also vary based upon one or more physiological parameters associated with the patient, such as the patient's temperature, blood oxygen concentration, EMG signal, etc. Furthermore, the shape of the frequency curve **530** can also vary based upon the particular drug administered to sedate the patient. For example, the drug type, drug class (e.g., hypnotic, analgesic, opiate, etc.), mechanism or method of delivery (inhalant, intravenous, ingestible, etc.) and/or

particular active ingredient (e.g., Propofol (TIVA), Sevoflurane, nitrous oxide, morphine, etc.) can each affect the shape of the frequency curve **530**. Variations in the frequency curve **530** make it more difficult for the depth of consciousness monitor **140** to accurately determine whether the patient is adequately sedated.

(64) Therefore, to improve accuracy, in one embodiment the depth of consciousness monitor's processor **220** analyzes the frequency curve **530** by considering one or more curve profiles associated with the patient and/or the drug administered. For example, in one embodiment, the processor **220** obtains physiological information regarding the patient from sensors **120** attached to the depth of consciousness monitor **140**. In other embodiments, the processor **220** obtains physiological information regarding the patient via a data port. For example, the data port can receive temperature, blood oxygen saturation, respiration rate, and/or other physiological parameter information from an separate monitor. In addition, the depth of consciousness monitor **140** can receive additional information regarding the patient and the drug via the data port, as well.

(65) For example, in some embodiments, the data port includes a wireless radio, a network adapter, a cable, an Ethernet adapter, a modem, a cellular telephone, etc., to receive patient and/or drug information. The patient and/or drug information is provided to the processor **220** to accurately interpret the frequency curve **530** derived from the EEG sensor **330** signal. In one embodiment, the data port includes a keyboard or other data entry device that allows the clinician to manually enter data relating a patient or drug parameters, such as those examples described above. Indeed, the processor **220** can include one or more EEG processing engines that are configured based upon the patient and/or drug data received by the depth of consciousness monitor **140**, as discussed in greater detail below.

(66) In some embodiments, the patient's frequency response graph **500** is processed as four distinct, non-overlapping frequency bands **550**, **552**, **554**, **556**. For example, the first frequency band, sometimes referred to as the delta band, is the portion of the graph **500** between 0 and 4 or about 4 Hz. The second frequency band, sometimes referred to as the theta band, is the portion of the graph **500** between 4 or about 4 Hz and 7 or about 7 Hz. The third frequency band, sometimes referred to as the alpha band, is the portion of the graph **500** between 7 or about 7 Hz and 12 or about 12 Hz; and the fourth frequency band, sometimes referred to as the beta band, is the portion of the graph **500** greater than 12 or about 12 Hz.

(67) In some embodiments, the depth of consciousness monitor **140** determines whether there is a peak **540** greater than a predetermined threshold in the frequency curve **530** anywhere within the alpha band **554**. If so, the monitor **140** may determine that the patient is adequately sedated. However, in some cases, the peak **540** can shift and appear outside of the alpha band **554**. For example, a sedated patient that is experiencing hypothermia may not manifest a peak in the alpha band; instead, the peak may shift to the theta or beta bands.

(68) Therefore, in one embodiment, the depth of consciousness monitor **140** does not limit its search for a peak **540** to a particular frequency value (e.g., 10 Hz) or a particular frequency band (e.g., alpha band **554**). Instead, in such an embodiment, the depth of consciousness monitor **140** scans across all frequencies (or a larger subset of frequencies than just those within the alpha band) to search for a peak **540** (e.g., across two or more frequency bands). A detected peak may be used to determine alone (or in combination with other patient and/or drug data) whether the patient is adequately sedated.

(69) The peak **540** can be defined in any of a variety of clinically-relevant manners. For example, the peak **540** can be defined based upon the slope of the curve segment on one or both sides of the peak **540**, the relative magnitude of the peak compared to the curve values at predetermined locations or offsets on either side of the peak **540**, the relative magnitude of the peak compared to the frequency curve **510** of the patient obtained prior to sedation, etc.

(70) In one embodiment, the processor **220** processes the patient's frequency spectra curve **510**, **530** as deformable curves by utilizing motion vector processing. For example, the processor **220**

compares each point (or a predetermined number of points) in the pre-sedation curve **510** to points within the sedation frequency curve **530** to match points having the greatest similarity (e.g., relative position with respect to its neighbors, pattern matching, sum of absolute differences, any pattern matching technique, etc.). The processor **220** determines one or more motion vectors **560** to describe the motion of the points from one curve **510** to the next **530**. Each motion vector **560** includes both direction and amplitude (e.g., distance traveled) information. Although the graph **500** includes curve **510**, **530** illustrated in the frequency domain (the x-axis represents frequency), the motion vectors **560** include time domain information. For example, the processor **220** can look at multiple frames of data (e.g., multiple graphs **500**) and employ pattern matching techniques (e.g., sum of absolute differences) to determine which points in the graphs **500** and their curves **510**, **530** to use to define the respective motion vectors **560**. In some embodiments, the motion vectors **560** are determined at 0.5, 1, 2, or 2.5 Hz intervals.

(71) One or more motion vector **560** profiles may be constructed based upon particular drug and patient data. For example, each drug used for sedation may be characterized by a unique set of motion vectors. When a patient is treated with a particular drug, and the patient's motion vectors match those of the drug (e.g., the drug profile), the processor **220** can determine that the patient is adequately sedated. Such profiles may be determined for any one or more of the patient's age, age classification (e.g., pediatric, adult, geriatric, etc.), sex, weight, body-mass index, genetic factors, etc., physiological parameters associated with the patient, such as the patient's temperature, blood oxygen concentration, EMG signal, etc., the particular drug administered to sedate the patient, the drug type, drug class (e.g., hypnotic, analgesic, opiate, etc.), mechanism or method of delivery (inhalant, intravenous, ingestible, etc.) and/or particular active ingredient (e.g., Propofol (TIVA), Sevoflurane, nitrous oxide, morphine, etc.). Such profiles may be stored within the depth of consciousness monitor's memory, or they may be retrieved from one or more data repositories stored at one or more remote locations (e.g., over a computer network, over the Internet, from a server, from the cloud, etc.).

(72) In another embodiment, the EEG front end circuitry is configured not to eliminate or filter out low frequencies. The EEG front end circuitry instead allows the processor **220** to determine slow waves (e.g., time-domain signals at or below 1, 0.5, and/or 0.2 Hz). The processor **220** can employ one or more phase coherence methods to detect phase coherence between one or more slow waves and one or more patient signals falling within one of the frequency bands **550**, **552**, **554**, **556**. For example, in some embodiments, phase coherence between a slow wave and a signal from the theta band **552** indicates that the patient is awake. Once the slow wave and signal from the theta band **552** are out of phase, the patient is sedated. In other embodiments, phase coherence analysis is performed to compare phase coherence between a selected slow wave and a different frequency band's signals (e.g., the delta band **550**, the alpha band **554**, and/or the beta band **556**). In some embodiments, the processor **220** performs phase coherence analysis between a selected slow wave and multiple signals between 4 and 50 Hz, e.g., every 0.2, 0.5, 1, or 2 Hz. In other embodiments, phase coherence is determined along the entire frequency spectrum.

(73) In yet another embodiment, the processor **220** generates and/or utilizes a mathematical or electrical model of brain activity to determine whether the patient is adequately sedated. The model can be used to predict what the EEG of a sedated patient should look like based upon a particular drug, drug delivery mechanism, concentration (or any other drug parameter, including those discussed above). Actual EEG signals may be compared to the signal predicted by the model to determine whether the patient is adequately sedated. The model can be constructed of various combinations of electrical components (e.g., resistors, capacitors, amplifiers, etc.) or computing elements.

(74) In one embodiment, brain modeling occurs by storing EEG signals from sedated patients in a memory location and categorized the EEG signals based upon any of a variety of drug and patient data information. For example, sedated EEG signals may be categorized based upon the particular

drug, dosage, concentration, delivery method, etc. used to treat the patient. A brain response model is constructed by combining the various data into a single model.

(75) In some embodiments, the processor **220** includes a pre-processor **602**, a compute engine **604**, and a post processor **606**, as illustrated in FIG. 5. The patient's EEG signal is received by the pre-processor **602**. The pre-processor **602** performs front end processing, such as one or more of filtering, amplification, A/D sampling, decimation, demodulation, etc. of the EEG signal. In some embodiments, the pre-processor **602** includes the EEG front end functionality discussed above with respect to FIG. 2. The compute engine **604** determines the level of patient sedation and/or depth of consciousness utilizing, for example, any of the techniques described herein. In one embodiment, the compute engine **604** determines an index value representative of the patient's sedation level. The post-processor **606** provides an indication of the patient's sedation level as well as other relevant information (e.g., system delay, as discussed above, other physiological parameter information, pass-through signals, etc.) for display to the clinician and/or transmission to a drug delivery device or other physiological monitor or information display station. In some embodiments, the post-processor **606** stores patient sedation, EEG signals, patient data and drug information in a memory location.

(76) Another embodiment of a processor **220** is illustrated in FIG. 6. The processor **220** includes a pre-processor **602**, multiple compute engines **604a**, **604b**, . . . **604n**, and decision logic **608**. Each compute engine **604a**, **604b**, . . . **604n** determines patient sedation information utilizing different processing approaches. For example, one compute engine **604** may determine patient sedation information utilizing motion vector analysis (e.g., as discussed above), one compute engine **604** may determine patient sedation information utilizing frequency coherence analysis (e.g., as discussed above), etc. Furthermore, each compute engine **604** can be drug or patient information specific. For example, the compute engine **604** may utilize historical information (either of the patient himself or from a model, etc.) to determine patient sedation. Each compute engine **604** could therefore correspond to a particular patient's age, age classification (e.g., pediatric, adult, geriatric, etc.), sex, weight, body-mass index, genetic factors, etc., physiological parameters, such as temperature, blood oxygen concentration, EMG signal, etc., the particular drug administered to sedate the patient, such as the drug type, drug class (e.g., hypnotic, analgesic, opiate, etc.), mechanism or method of delivery (inhalant, intravenous, ingestible, etc.) and/or particular active ingredient (e.g., Propofol (TIVA), Sevoflurane, nitrous oxide, morphine, etc.). The compute engines **604** may operate simultaneously to parallel process EEG information.

(77) A decision logic module **608** receives the outputs of each compute engine **604** and applies logic to determine the best estimate of the patient's sedation level. For example, in some embodiments, the decision logic module **608** averages or weighted averages the outputs of the compute engines **604**. In other embodiments, the decision logic module **608** selects one or more compute engine outputs based upon known information about the patient and/or drug(s) used for sedation. The decision logic output **610** can indicate one or more parameters relevant to patient sedation. For example, in some embodiments, the decision logic output **610** includes suppression bar, EMG estimation, patient sedation index, drug type and patient age estimates. If any one or more decision logic outputs do not match actual drug or patient profile information, an alarm can activate. In other embodiments, the clinician manually compares the decision logic outputs to actual drug and patient profile information to confirm the accuracy of the depth of consciousness monitor **140**.

(78) Another embodiment of a depth of consciousness monitor's processor **220** is illustrated in FIG. 7. The processor **602** includes a pre-processor **602**, compute engines **604** and decision logic **608**, as discussed above with respect to FIG. 6. In addition, the processor **220** includes an EEG engine **620** and an EMG engine **630**. The EEG and EMG engines receive a pre-processed EEG signal from the pre-processor **602**. The pre-processed EEG signal will generally contain both EEG and EMG content. For example, EEG content describes the electrical activity within the patient's brain and

the EMG content describes the electrical activity associated with the muscular contractions in the patient's forehead, near the EEG sensor. The EEG and EMG engines **620, 630** separate the EEG and EMG content from the pre-processed EEG signal. The outputs of the EEG and EMG engines **620, 630** communicate with the inputs of one or more compute engines **604**. The EEG signal from the EEG engine provides an indication of the patient's hypnotic state, while the EMG engine provides an indication of the patient's analgesic response, or pain state. Separating the two provides more information about the patient's state, and allows improved depth of consciousness processing. When EMG content is included in the EEG signal, the frequency response curve is flatter at higher frequencies (e.g., at frequencies in the beta band).

(79) FIG. **8** illustrates one embodiment of a process **700** to determine a patient's sedation level that can be implemented by any of the processors described above. The process **700** begins at block **702**. At block **702**, the process **700** receives an EEG signal from a patient. At block **704**, the process **700** receives treatment data. The treatment data may include one or more of patient data and drug profile information. The patient data can include any of the patient data or drug profile information described above. At block **706**, the process **700** selects a computing engine based upon one or more treatment data. At block **708**, the process **700** computes patient sedation information using EEG information and the selected computing engine. The patient sedation information can include one or more of a patient sedation level or index, an EMG level, a prediction of the drug used to sedate the patient, a prediction of the patient's age, etc. The process **700** ends at block **708**.

(80) FIG. **9** illustrates another embodiment of a process **800** to determine a patient's sedation level that can be implemented by any of the processors described above. The process **800** begins at block **802**. At block **802**, the process **800** receives an EEG signal from a patient. At block **804**, the process **800** receives treatment data. The treatment data may include one or more of patient data and drug profile information. The patient data can include any of the patient data or drug profile information described above. At block **806**, the process **800** computes patient sedation information with parallel computing engines using the EEG information. The patient sedation information can include one or more of a patient sedation level or index, an EMG level, a prediction of the drug used to sedate the patient, a prediction of the patient's age, etc. At block **808**, the process **800** determines patient sedation information by selecting the output of one of the parallel computing engines, or by combining one or more computing engine outputs (e.g., averaging, weighted averaging, etc.). The process **800** ends at block **808**.

(81) FIG. **10** illustrates one embodiment of a depth of consciousness monitoring system **1000**. The system **1000** includes a depth of consciousness monitor assembly **1002**, a multi-parameter monitor **1012**, and a sensor **1014**. The monitor assembly **1002** includes a depth of consciousness processor **1003**, which can include any of the processors described above. In some embodiments, the processor **1003** is configured to perform one or more of the methods described above.

(82) The assembly **1002** may be provided in the form of a cable. For example, the assembly **1002** may include one or more cables **1004** (or cable portions) that terminate in connectors **1005, 1008** located at the cable ends **1006, 1010**. In the illustrated embodiment of FIG. **10**, the assembly **1002** includes two cables **1004**. The first cable **1004** has two ends and is coupled to the processor **1003** at one end and terminates at a connector **1005** at the other end **1006**. In one embodiment, the connector **1005** (which is one embodiment of an interface, such as a multi-parameter monitor interface) is configured facilitate communication between the processor **1003** and a medical device, such as a physiological monitor, display instrument, and/or a multi-parameter monitor **1012**, etc. In some embodiments, the connector **1005** receives power from a multi-parameter monitor **1012** to power the depth of consciousness processor **1003**. In some embodiments, the processor **1003** is configured to consume less than about 250 mW, 500 mW or 1 W at about 4.75 V, 5 V or 5.25 V.

(83) Physiological signals generated by the depth of consciousness processor **1003** are communicated to the multi-parameter monitor **1012** via the connector **1005**. The multi-parameter monitor **1012** is configured to display one or more of the signals generated by the depth of

consciousness processor **1003**. In one embodiment, the cable **1004** that terminates at the multi-parameter monitor **1012** connector **1005** is configured to provide and/or receive power, ground, data+ and data- signals. For example, in one embodiment, the cable **1004** includes four conductors, one each for power, ground, data+ and data-.

(84) An adapter or coupler (not shown) may be provided to facilitate coupling of the connector **1005** to the multi-parameter monitor **1012**. For example, an adapter having first and second ends can be configured to have different shapes and pin configurations to allow communication and physical coupling of the connector **1005** to the multi-parameter monitor **1012**. In some embodiment, the adapter (not shown) also includes conditioning circuitry to facilitate communication and/or power transmission between the multi-parameter monitor **1012** and the processor **1003**. For example, the adapter may provide voltage regulation, electrical isolation, signal multiplexing, etc.

(85) The second cable **1004** has two ends and is coupled to the processor **1003** at one end and terminates at a connector **1008** at the other end **1010**. In one embodiment, the connector **1008** is configured to facilitate communication with a physiological sensor **1014**, such as an EEG sensor, and/or any other sensor described above via an interface **1015** (e.g., interface **450** of FIG. 3). In one embodiment, power from the multi-parameter monitor **1012** is directly or indirectly (e.g., after further filtering, conditioning, pulsing, etc. by the processor **1003**) communicated to the sensor **1014**. Signals (e.g., e.g., measured patient signals) from the sensor **1014** are communicated to the processor **1003** via the interface **1015**, which can be coupled to the connector **1008**.

(86) FIG. 11 illustrates another embodiment of a depth of consciousness monitoring assembly **1002** coupled to a multi-parameter monitor (sometimes referred to as a multi-parameter instrument) **1012**. The multi-parameter monitor **1012** is configured to receive and display a plurality of physiological parameters received from a patient monitoring device, such as, but not limited to, the depth of consciousness monitoring assembly **1002**. The multi-parameter monitor **1012** includes a display **1020**. The display **1020** is configured to display a plurality of physiological signals **1022** related to a medical patient. In some embodiments, the display **1020** can be configured to display only selected or groups of physiological signals **1022**. In some embodiments, the monitor **1012** can be configured to display a particular view or mode on the display **1020**. The view or mode can include one or more pre-selected groupings of physiological signals to display. Examples of different views that may be provided via the display **1020** are discussed below with respect to FIGS. 14-16. Other views, in addition to or instead of those illustrated in FIGS. 14-16 may be displayed on the multi-parameter monitor **1012** display **1020**, as well.

(87) In some embodiments, the multi-parameter monitor **1012** also includes a removable module **1024**. The removable module **1024** can include a physiological monitor configured to determine one or more physiological parameters associated with the medical patient. For example, in some embodiments, the removable module **1024** includes a respiration rate monitor, a blood oxygen saturation monitor, a blood gas monitor, a carbon monoxide monitor, an ECG monitor, an EKG monitor, a blood pressure monitor, a temperature monitor, a heart rate monitor, etc., or a combination of any one or more of the foregoing.

(88) In the illustrated embodiment of FIG. 11, the depth of consciousness monitor assembly **1002** only includes one cable **1004**. A first end of the cable **1004** terminates at a connector (not shown) that is attached to the multi-parameter monitor **1012**. The second end of the cable **1003** includes the depth of consciousness processor **1003** and connector **1008**, which are integrated within a single housing assembly. The connector end of a sensor **1014** is shown attached to the depth of consciousness monitor assembly's **1002** cable's **1003** second end.

(89) FIG. 12 illustrates another embodiment of a depth of consciousness monitor assembly **1002**. The processor **1003** is positioned between the ends **1006**, **1010** of the assembly **1002**. The length of the cable **1004** attached to the connector **1008** configured to attach to a sensor (not shown) may be shorter than the length of the cable **1004** attached to the connector **1005** configured to attach to the

multi-parameter monitor (not shown). The shorter sensor cable **1004** length can provide additional comfort and less pulling on the sensor when attached to the patient. FIG. **13** illustrates the depth of consciousness monitor assembly **1002** coupled to a sensor **1014**. The sensor **1014** can include any of the EEG sensors described above.

(90) FIGS. **14-16** illustrate views of various parameters **1022** that may be displayed on the multi-parameter monitor **1012** display **1020**. The embodiment of FIG. **14** illustrates an EEG view of a multi-parameter monitor **1012**. The multi-parameter monitor **1012** view includes a numeric value indicator (e.g., EEG data, insufficient EEG data, patent state index (PSI) value), or any other value described herein, etc.), a bar-graph indicator, menu indicators, date and time indicators, message indicators, physiological waveform indicators, and system status indicators. The physiological waveform indicators can display each of the waveforms received from each electrode (e.g., R2, R1, L1) of an sensor **1014**, such as an EEG sensor.

(91) FIG. **15** illustrates a trend view of a multi-parameter monitor **1012**. The multi-parameter monitor **1012** view includes a primary indicator or display and a secondary indicator or display. The primary indicator displays the trend of one or more physiological parameters (e.g., PSI, etc.) over time. One or more secondary indicators can display additional physiological parameters of the medical patient, including but not limited to, EMG, and SR. In one embodiment, the secondary indicators display information in the same format (e.g., waveform, solid waveform, bargraph, etc.) as the primary (e.g., trend plot) indicator, but at a smaller size. In other embodiments, the secondary indicators display information in a different format than the primary (e.g., trend plot, etc.) indicator. FIG. **16** illustrates a density spectral array view of a multi-parameter monitor **1012**. The multi-parameter monitor **1012** view includes a spectral density indicator

(92) Each of the displayed physiological parameters can be determined by the depth of consciousness processor **1003**. In addition, the multi-parameter monitor **1012** can be configured to display any one or more of the parameters discussed above, as well as other parameters, such as signals from the removable module **1024**, when provided.

(93) All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

(94) Depending on the embodiment, certain acts, events, or functions of any of the processes or algorithms described herein can be performed in a different sequence, can be added, merged, or left out altogether (e.g., not all described operations or events are necessary for the practice of the algorithm). Moreover, in certain embodiments, operations or events can be performed concurrently, e.g., through multi-threaded processing, interrupt processing, or multiple processors or processor cores or on other parallel architectures, rather than sequentially.

(95) The various illustrative logical blocks, modules, routines, and algorithm steps described in connection with the embodiments disclosed herein can be implemented as electronic hardware, computer software, or combinations of both. To clearly illustrate this interchangeability of hardware and software, various illustrative components, blocks, modules, and steps have been described above generally in terms of their functionality. Whether such functionality is implemented as hardware or software depends upon the particular application and design constraints imposed on the overall system. The described functionality can be implemented in varying ways for each particular application, but such implementation decisions should not be interpreted as causing a departure from the scope of the disclosure.

(96) The steps of a method, process, routine, or algorithm described in connection with the embodiments disclosed herein can be embodied directly in hardware, in a software module executed by a processor, or in a combination of the two. A software module can reside in RAM memory, flash memory, ROM memory, EPROM memory, EEPROM memory, registers, hard disk, a removable disk, a CD-ROM, or any other form of a non-transitory computer-readable storage medium. An example storage medium can be coupled to the processor such that the processor can

read information from, and write information to, the storage medium. In the alternative, the storage medium can be integral to the processor. The processor and the storage medium can reside in an ASIC. The ASIC can reside in a user terminal. In the alternative, the processor and the storage medium can reside as discrete components in a user terminal.

(97) Conditional language used herein, such as, among others, “can,” “could,” “might,” “may,” “e.g.,” and the like, unless specifically stated otherwise, or otherwise understood within the context as used, is generally intended to convey that certain embodiments include, while other embodiments do not include, certain features, elements and/or steps. Thus, such conditional language is not generally intended to imply that features, elements and/or steps are in any way required for one or more embodiments or that one or more embodiments necessarily include logic for deciding, with or without author input or prompting, whether these features, elements and/or steps are included or are to be performed in any particular embodiment. The terms “comprising,” “including,” “having,” and the like are synonymous and are used inclusively, in an open-ended fashion, and do not exclude additional elements, features, acts, operations, and so forth. Also, the term “or” is used in its inclusive sense (and not in its exclusive sense) so that when used, for example, to connect a list of elements, the term “or” means one, some, or all of the elements in the list.

(98) Conjunctive language such as the phrase “at least one of X, Y and Z,” unless specifically stated otherwise, is to be understood with the context as used in general to convey that an item, term, etc. may be either X, Y, or Z, or a combination thereof. Thus, such conjunctive language is not generally intended to imply that certain embodiments require at least one of X, at least one of Y and at least one of Z to each be present.

(99) While the above detailed description has shown, described, and pointed out novel features as applied to various embodiments, it can be understood that various omissions, substitutions, and changes in the form and details of the devices or algorithms illustrated can be made without departing from the spirit of the disclosure. As can be recognized, certain embodiments of the inventions described herein can be embodied within a form that does not provide all of the features and benefits set forth herein, as some features can be used or practiced separately from others. The scope of certain inventions disclosed herein is indicated by the appended claims rather than by the foregoing description. All changes which come within the meaning and range of equivalency of the claims are to be embraced within their scope.

Claims

1. A depth of consciousness monitor configured to determine a level of sedation of a medical patient, the depth of consciousness monitor comprising: an EEG interface configured to receive an EEG signal from an EEG sensor; an EEG front end configured to pre-process the EEG signal, wherein the EEG signal is assigned a first time stamp; a processor, configured to determine the level of sedation of the medical patient based at least upon the pre-processed EEG signal, the processor comprising: two or more parallel computing engines, each configured to receive as an input a same first time stamped pre-processed EEG signal and compute a possible sedation level according to a different processing approach, each processing approach configured to simultaneously calculate the possible sedation level using the same first time stamped pre-processed EEG signal; and a decision logic module, configured to arbitrate the possible sedation level computations as computed by the two or more parallel computing engines on the same first time stamped pre-processed EEG signal and based on the arbitration, determine a patient sedation index corresponding to an estimated level of sedation of the medical patient, wherein the arbitration comprises selecting a subset of possible sedation levels generated by the two or more parallel compute engines, wherein the arbitration is based at least on data associated with at least one sedation drug acting on the medical patient and the selected subset of possible sedation levels

- generated by the two or more parallel compute engines; and a data port configured to transmit the level of sedation of the medical patient.
2. The depth of consciousness monitor of claim 1, wherein the data port comprises a multi-parameter physiological monitor interface configured to receive power from a multi-parameter physiological monitor and provide at least the level of sedation of the medical patient to the multi-parameter physiological monitor.
 3. The depth of consciousness monitor of claim 1, wherein at least one of the computing engines is configured to implement a motion vector process to compute one of the possible sedation levels.
 4. The depth of consciousness monitor of claim 1, wherein at least one of the computing engines is configured to implement a phase coherence process to compute one of the possible sedation levels.
 5. The depth of consciousness monitor of claim 1, wherein at least one of the computing engines is configured to utilize a brain model to compute one of the possible sedation levels.
 6. The depth of consciousness monitor of claim 1, wherein the EEG front end comprises an EEG engine and an EMG engine configured to extract EEG information and EMG information from the EEG signal, respectively.
 7. The depth of consciousness monitor of claim 1, wherein the data port comprises a display.
 8. The depth of consciousness monitor of claim 1, wherein the data port comprises a wireless communication device.
-